117976-90-6 | Rabeprazole sodium

Packsize	Purity	Availability	Price	Discounted Price
100mg	98%	in stock	$44.00	$31.00
1g	98%	in stock	$105.00	$74.00
5g	98%	in stock	$365.00	$255.00

Description

• Catalog Number: AB78788
• Chemical Name: Rabeprazole sodium
• CAS Number: 117976-90-6
• Molecular Formula: C18H20N3NaO3S
• Molecular Weight: 381.4245
• MDL Number: MFCD02092688
• SMILES: COCCCOc1ccnc(c1C)CS(=O)c1[n-]c2c(n1)cccc2.[Na+]

Computed Properties

• Complexity: 446
• Covalently-Bonded Unit Count: 2
• Heavy Atom Count: 26
• Hydrogen Bond Acceptor Count: 7
• Rotatable Bond Count: 8
• Undefined Atom Stereocenter Count: 1

Upstream Synthesis Route

Rabeprazole sodium, a class of proton-pump inhibitors, plays a significant role in chemical synthesis. Its application in the manufacturing process is indispensable for the production of pharmaceutical compounds and other materials. As a versatile compound, Rabeprazole sodium serves as a key intermediate in the synthesis of various drugs, including those used in the treatment of gastric acid-related disorders. By efficiently facilitating chemical reactions and providing crucial functionalities, Rabeprazole sodium contributes to the creation of high-quality and effective pharmaceutical products. Its role in chemical synthesis underscores its importance in the pharmaceutical industry and highlights its value as a fundamental building block in the creation of diverse therapeutic agents and related substances.

Literature

• Systems pharmacological analysis of drugs inducing stevens-johnson syndrome and toxic epidermal necrolysis.

  Chemical research in toxicology 20150518

• Systematic toxicity mechanism analysis of proton pump inhibitors: an in silico study.

  Chemical research in toxicology 20150316

• AL3810, a multi-tyrosine kinase inhibitor, exhibits potent anti-angiogenic and anti-tumour activity via targeting VEGFR, FGFR and PDGFR.

  Journal of cellular and molecular medicine 20121001

• Effects of a proton pump inhibitor on the physiological accumulation of fluoro-2-deoxy-D-glucose (FDG) in FDG-positron emission tomography.

  Surgery today 20121001

• Rabeprazole 10 mg q.d.s. decreases 24-h intragastric acidity significantly more than rabeprazole 20 mg b.d. or 40 mg o.m., overcoming CYP2C19 genotype.

  Alimentary pharmacology & therapeutics 20121001

• Esophageal motor dysfunction plays a key role in GERD with globus sensation--analysis of factors promoting resistance to PPI therapy.

  Scandinavian journal of gastroenterology 20120901

• Evaluation of six proton pump inhibitors as inhibitors of various human cytochromes P450: focus on cytochrome P450 2C19.

  Drug metabolism and disposition: the biological fate of chemicals 20120901

• Meta-analysis: esomeprazole or rabeprazole vs. first-generation pump inhibitors in the treatment of Helicobacter pylori infection.

  Alimentary pharmacology & therapeutics 20120901

• Newly discovered angiogenesis inhibitors and their mechanisms of action.

  Acta pharmacologica Sinica 20120901

• Ability of rabeprazole to prevent gastric mucosal damage from clopidogrel and low doses of aspirin depends on CYP2C19 genotype.

  Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association 20120801

• Comparison of lafutidine and rabeprazole in 7-day second-line amoxicillin- and metronidazole-containing triple therapy for Helicobacter pylori: a pilot study.

  Helicobacter 20120801

• Pilot studies to identify the optimum duration of concomitant Helicobacter pylori eradication therapy in Thailand.

  Helicobacter 20120801

• Rabeprazole for the treatment of acid-related disorders.

  Expert review of gastroenterology & hepatology 20120801

• Electrical bioimpedance gastric motility measurement based on an electrical-mechanical composite mechanism.

  World journal of gastroenterology 20120707

• Segmental changes in smooth muscle contraction as a predictive factor of the response to high-dose proton pump inhibitor treatment in patients with functional chest pain.

  Journal of gastroenterology and hepatology 20120701

• Randomized, open-label, single-dose, crossover, relative bioavailability study in healthy adults, comparing the pharmacokinetics of rabeprazole granules administered using soft food or infant formula as dosing vehicle versus suspension.

  Clinical therapeutics 20120701

• Dual therapy for third-line Helicobacter pylori eradication and urea breath test prediction.

  World journal of gastroenterology 20120607

• Comparison of sequential and 7-, 10-, 14-d triple therapy for Helicobacter pylori infection.

  World journal of gastroenterology 20120521

• A randomized open-label trial of on-demand rabeprazole vs ranitidine for patients with non-erosive reflux disease.

  World journal of gastroenterology 20120521

• Effect of pretreatment with Lactobacillus gasseri OLL2716 on first-line Helicobacter pylori eradication therapy.

  Journal of gastroenterology and hepatology 20120501

• Predicting the efficacy of proton pump inhibitors in patients with non-erosive reflux disease before therapy using dual-channel 24-h esophageal pH monitoring.

  Journal of gastroenterology and hepatology 20120501

• Dose-response relationships of rabeprazole 5, 10, 20, and 40 mg once daily on suppression of gastric acid secretion through the night in healthy Japanese individuals with different CYP2C19 genotypes.

  European journal of clinical pharmacology 20120501

• Symptoms and quality of life in underweight gastroesophageal reflux disease patients and therapeutic responses to proton pump inhibitors.

  Journal of gastroenterology and hepatology 20120501

• Predictors of acid suppression success in patients with chronic laryngitis.

  Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society 20120501

• Comparison of PPIs and H2-receptor antagonists plus prokinetics for dysmotility-like dyspepsia.

  World journal of gastroenterology 20120407

• A comparison of the acid-inhibitory effects of esomeprazole and rabeprazole in relation to pharmacokinetics and CYP2C19 polymorphism.

  Alimentary pharmacology & therapeutics 20120401

• In vitro release profile of anti-ulcer drug rabeprazole from biocompatible psyllium-PVA hydrogels.

  Journal of materials science. Materials in medicine 20120401

• Efficacy of twice-daily rabeprazole for reflux esophagitis patients refractory to standard once-daily administration of PPI: the Japan-based TWICE study.

  The American journal of gastroenterology 20120401

• Healing erosive esophagitis with a proton pump inhibitor: the more the merrier?

  The American journal of gastroenterology 20120401

• [Clinical effects of dalitong granule combined proton pump inhibitors on gastroesophageal reflux disease].

  Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi jiehe zazhi = Chinese journal of integrated traditional and Western medicine 20120401

• Influence of different proton pump inhibitors on activity of cytochrome P450 assessed by [(13)C]-aminopyrine breath test.

  Journal of clinical pharmacology 20120301

• Comparison of patients of chronic laryngitis with and without troublesome reflux symptoms.

  Journal of gastroenterology and hepatology 20120301

• Ten-day sequential therapy is more effective than proton pump inhibitor-based therapy in Korea: a prospective, randomized study.

  Journal of gastroenterology and hepatology 20120301

• Combination of angiotensin II receptor blockers promotes proton pump inhibitor-based healing of reflux esophagitis.

  Journal of gastroenterology 20120301

• A large-scale nationwide multicenter prospective observational study of triple therapy using rabeprazole, amoxicillin, and clarithromycin for Helicobacter pylori eradication in Japan.

  Journal of gastroenterology 20120301

• Rikkunshito improves symptoms in PPI-refractory GERD patients: a prospective, randomized, multicenter trial in Japan.

  Journal of gastroenterology 20120301

• Prospective single-arm trial of two-week rabeprazole treatment for ulcer healing after gastric endoscopic submucosal dissection.

  Digestive endoscopy : official journal of the Japan Gastroenterological Endoscopy Society 20120301

• Long-term administration of PPI reduces treatment failures after esophageal variceal band ligation: a randomized, controlled trial.

  Journal of gastroenterology 20120201

• Randomised clinical trial: a comparative study of 10-day sequential therapy with 7-day standard triple therapy for Helicobacter pylori infection in naïve patients.

  Alimentary pharmacology & therapeutics 20120101

• Impact of acid inhibition on esophageal mucosal injury induced by low-dose aspirin.

  Digestion 20120101

• The eradicating Helicobacter pylori infection in duodenal ulcer patients by three short-term triple therapies in China: a multicenter clinical comparative study.

  Hepato-gastroenterology 20120101

• Effects of PPIs and an H2 blocker on the antiplatelet function of clopidogrel in Japanese patients under dual antiplatelet therapy.

  Journal of atherosclerosis and thrombosis 20120101

• Response to gastroesophageal reflux disease therapy: assessment at 4 weeks predicts response/non-response at 8 weeks.

  Digestion 20120101

• Hypomagnesemia associated with a proton pump inhibitor.

  Internal medicine (Tokyo, Japan) 20120101

• Antiprotozoal activity of proton-pump inhibitors.

  Bioorganic & medicinal chemistry letters 20111215

• Practice pattern of gastroenterologists for the management of GERD under the minimal influence of the insurance reimbursement guideline: a multicenter prospective observational study.

  Journal of Korean medical science 20111201

• Response of unexplained chest pain to proton pump inhibitor treatment in patients with and without objective evidence of gastro-oesophageal reflux disease.

  Gut 20111101

• Investigation of pretreatment prediction of proton pump inhibitor (PPI)-resistant patients with gastroesophageal reflux disease and the dose escalation challenge of PPIs-TORNADO study: a multicenter prospective study by the Acid-Related Symptom Research Group in Japan.

  Journal of gastroenterology 20111101

• Relative bioavailability of a 5 mg mosapride/10 mg rabeprazole fixed dose combination tablet versus separate single tablets in healthy volunteers: a single-dose randomized open-label crossover study.

  Current medical research and opinion 20111101

• A randomized trial of standard-dose versus half-dose rabeprazole, clarithromycin, and amoxicillin in the treatment of Helicobacter pylori infection.

  European journal of gastroenterology & hepatology 20111001

• Does BMI affect the clinical efficacy of proton pump inhibitor therapy in GERD? The case for rabeprazole.

  European journal of gastroenterology & hepatology 20111001

• Regression of multiple duodenal hyperplastic polyps following Helicobacter pylori eradication.

  Digestive endoscopy : official journal of the Japan Gastroenterological Endoscopy Society 20111001

• Development and validation of a high-performance liquid chromatography-tandem mass spectrometry method for the determination of the novel inhibitor of angiogenesis E-3810 in human plasma and its application in a clinical pharmacokinetic study.

  Journal of mass spectrometry : JMS 20111001

• Randomised clinical trial: rabeprazole plus aspirin is not inferior to rabeprazole plus clopidogrel for the healing of aspirin-related peptic ulcer.

  Alimentary pharmacology & therapeutics 20110901

• '7, 10 and 14-days rabeprazole-based standard triple therapies for H. pylori eradication: are they still effective? A randomized trial'.

  Acta gastro-enterologica Belgica 20110901

• Acid-suppressive effect of rabeprazole 5 mg and 10 mg once daily by 24-hour esophageal pH monitoring in patients with non-erosive reflux disease in Japan: a multicenter, randomized, parallel-group, double-blind pharmacodynamic study.

  Digestive diseases and sciences 20110801

• A reverse method for diversity introduction of benzimidazole to synthesize H(+)/K(+)-ATP enzyme inhibitors.

  Bioorganic & medicinal chemistry letters 20110715

• Profiling of a prescription drug library for potential renal drug-drug interactions mediated by the organic cation transporter 2.

  Journal of medicinal chemistry 20110714

• Prospective, observational study using rabeprazole in 455 patients with laryngopharyngeal reflux disease.

  European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery 20110601

• Pharmacokinetics and tolerability of rabeprazole in children 1 to 11 years old with gastroesophageal reflux disease.

  Journal of pediatric gastroenterology and nutrition 20110601

• Efficacy of 2-week, second-line Helicobacter pylori eradication therapy using rabeprazole, amoxicillin, and metronidazole for the Japanese population.

  Helicobacter 20110601

• The role of Acid in functional dyspepsia.

  The American journal of gastroenterology 20110601

• Selective inactivation of a human neuronal silencing phosphatase by a small molecule inhibitor.

  ACS chemical biology 20110520

• [A case of acute renal failure due to interstitial nephritis likely induced by rabeprazole].

  Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine 20110510

• Rabeprazole impedes the development of reflux-induced esophageal cancer in a surgical rat model.

  Digestive diseases and sciences 20110501

• A randomized controlled trial of rebamipide plus rabeprazole for the healing of artificial ulcers after endoscopic submucosal dissection.

  Journal of gastroenterology 20110501

• Dissociation and dispersion of claudin-3 from the tight junction could be one of the most sensitive indicators of reflux esophagitis in a rat model of the disease.

  Journal of gastroenterology 20110501

• Incurred sample reanalysis (ISR): a decisive tool in bioanalytical research.

  Bioanalysis 20110501

• Characteristics of non-erosive gastroesophageal reflux disease refractory to proton pump inhibitor therapy.

  World journal of gastroenterology 20110414

• Relevance and characteristics of gastroesophageal reflux in adult patients with otitis media with effusion.

  Auris, nasus, larynx 20110401

• An open-label, parallel, multiple-dose study comparing the pharmacokinetics and gastric acid suppression of rabeprazole extended-release with esomeprazole 40 mg and rabeprazole delayed-release 20 mg in healthy volunteers.

  Alimentary pharmacology & therapeutics 20110401

• Pharmacogenetic determinants for interindividual difference of tacrolimus pharmacokinetics 1 year after renal transplantation.

  Journal of clinical pharmacy and therapeutics 20110401

• Comparison of the efficacy of irsogladine maleate and famotidine for the healing of gastric ulcers after Helicobacter pylori eradication therapy: a randomized, controlled, prospective study.

  Scandinavian journal of gastroenterology 20110301

• Effect of rabeprazole treatment on health-related quality of life and symptoms in patients with reflux esophagitis: a prospective multicenter observational study in Japan.

  Journal of gastroenterology 20110301

• Clinical usefulness of limited sampling strategies for estimating AUC of proton pump inhibitors.

  Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan 20110301

• E-3810 is a potent dual inhibitor of VEGFR and FGFR that exerts antitumor activity in multiple preclinical models.

  Cancer research 20110215

• Esophageal eosinophilic infiltration responds to proton pump inhibition in most adults.

  Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association 20110201

• Eosinophilic esophagitis and gastroesophageal reflux disease: there and back again.

  Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association 20110201

• Improvements in Helicobacter pylori eradication rates through clinical CYP2C19 genotyping.

  Nagoya journal of medical science 20110201

• Non-erosive reflux disease (NERD), symptomatic and asymptomatic erosive reflux disease (ERD): from hypersensitive to hyposensitive esophagus.

  Digestive diseases and sciences 20110101

• Randomised clinical trial: a multicentre, double-blind, placebo-controlled study on the efficacy and safety of rabeprazole 5 mg or 10 mg once daily in patients with non-erosive reflux disease.

  Alimentary pharmacology & therapeutics 20110101

• Study of the pharmacokinetics and intragastric pH of rabeprazole given as successive intravenous infusion to healthy Chinese volunteers.

  European journal of clinical pharmacology 20110101

• Randomised clinical trial: a novel rabeprazole extended release 50 mg formulation vs. esomeprazole 40 mg in healing of moderate-to-severe erosive oesophagitis - the results of two double-blind studies.

  Alimentary pharmacology & therapeutics 20110101

• Safety and efficacy of long-term maintenance therapy with oral dose of rabeprazole 10 mg once daily in Japanese patients with reflux esophagitis.

  Internal medicine (Tokyo, Japan) 20110101

• Response to air insufflation in patients with non-erosive gastro-oesophageal reflux disease (NERD).

  The Journal of international medical research 20110101

• Proton pump inhibitors inhibit metformin uptake by organic cation transporters (OCTs).

  PloS one 20110101

• Comparison of the effects of omeprazole and rabeprazole on ticlopidine metabolism in vitro.

  Journal of pharmacological sciences 20110101

• Effect of PPI (rabeprazole) on reflux esophagitis after total gastrectomy.

  Hepato-gastroenterology 20110101

• Gastric wash-based molecular testing for antibiotic resistance in Helicobacter pylori.

  Digestion 20110101

• Risk factors for relapse of erosive GERD during long-term maintenance treatment with proton pump inhibitor: a prospective multicenter study in Japan.

  Journal of gastroenterology 20101201

• Prevalence and symptom pattern of pathologic esophageal acid reflux in patients with functional dyspepsia based on the Rome III criteria.

  The American journal of gastroenterology 20101201

• The effect of cytochrome P2C19 and interleukin-1 polymorphisms on H. pylori eradication rate of 1-week triple therapy with omeprazole or rabeprazole, amoxycillin and clarithromycin in Chinese people.

  Journal of clinical pharmacy and therapeutics 20101201

• Enantioseparation of rabeprazole and omeprazole by nonaqueous capillary electrophoresis with an ephedrine-based ionic liquid as the chiral selector.

  Biomedical chromatography : BMC 20101201

• Editorial: Reflux, dyspepsia, and Rome III (or Rome IV?).

  The American journal of gastroenterology 20101201

• [Efficacy and safety of concomitant use of rabeprazole during dual-antiplatelet therapy with clopidogrel and aspirin after drug-eluting stent implantation: a retrospective cohort study].

  Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan 20101201

• Effect of CYP2C19 genotypes on the pharmacokinetic/pharmacodynamic relationship of rabeprazole after a single oral dose in healthy Chinese volunteers.

  European journal of clinical pharmacology 20101101

• Efficacy and tolerability of first-line triple therapy with levofloxacin and amoxicillin plus esomeprazole or rabeprazole for the eradication of Helicobacter pylori infection and the effect of CYP2C19 genotype: a 1-week, randomized, open-label study in Chinese adults.

  Clinical therapeutics 20101101

• Comparison between the effect of omeprazole and rabeprazole on the antiplatelet action of clopidogrel.

  Circulation journal : official journal of the Japanese Circulation Society 20101001

• [A case of mucosa-associated lymphoid tissue lymphoma with penicillin allergy successfully treated with levofloxacin, minomycin and rabeprazole].

  Gan to kagaku ryoho. Cancer & chemotherapy 20101001

• Rabeprazole is effective in treating laryngopharyngeal reflux in a randomized placebo-controlled trial.

  Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association 20100901

• Comparison of quinine and rabeprazole with quinine monotherapy in the treatment of uncomplicated falciparum malaria.

  Journal of vector borne diseases 20100901

• Value of barium swallow studies in predicting the response to rabeprazole in elderly patients with laryngopharyngeal reflux disease and nonerosive reflux disease in particular.

  The Annals of otology, rhinology, and laryngology 20100901

• Identification, isolation and characterization of new impurity in rabeprazole sodium.

  Journal of pharmaceutical and biomedical analysis 20100801

• Rabeprazole can overcome the impact of CYP2C19 polymorphism on quadruple therapy.

  Helicobacter 20100801

• How to manage Helicobacter pylori after sequential therapy failure?

  Journal of clinical gastroenterology 20100701

• Proton-pump inhibitor as palliative care for chemotherapy-induced gastroesophageal reflux disease in pancreatic cancer patients.

  Journal of palliative medicine 20100701

• Patients vote with their feet for 'On demand' rabeprazole in the maintenance treatment phase of reflux oesophagitis.

  Alimentary pharmacology & therapeutics 20100701

• Relationship between low-dose aspirin-induced gastric mucosal injury and intragastric pH in healthy volunteers.

  Digestive diseases and sciences 20100601

• Incidence and risk factor of fundic gland polyp and hyperplastic polyp in long-term proton pump inhibitor therapy: a prospective study in Japan.

  Journal of gastroenterology 20100601

• Pharmacogenetics of esomeprazole or rabeprazole-based triple therapy in Helicobacter pylori eradication in Hong Kong non-ulcer dyspepsia Chinese subjects.

  Journal of clinical pharmacy and therapeutics 20100601

• Impact of oesophagitis classification in evaluating healing of erosive oesophagitis after therapy with proton pump inhibitors: a pooled analysis.

  European journal of gastroenterology & hepatology 20100501

• Effects of a single dose of rabeprazole 20 mg and pantoprazole 40 mg on 24-h intragastric acidity and oesophageal acid exposure: a randomized study in gastro-oesophageal reflux disease patients with a history of nocturnal heartburn.

  Alimentary pharmacology & therapeutics 20100501

• Clinical trial: maintenance intermittent therapy with rabeprazole 20 mg in patients with symptomatic gastro-oesophageal reflux disease - a double-blind, placebo-controlled, randomized study.

  Alimentary pharmacology & therapeutics 20100501

• Observational comparative trial of the efficacy of proton pump inhibitors versus histamine-2 receptor antagonists for uninvestigated dyspepsia.

  Journal of gastroenterology and hepatology 20100501

• Transfer and distribution of amoxicillin in the rat gastric mucosa and gastric juice and the effects of rabeprazole.

  Acta pharmacologica Sinica 20100401

• Ten-day sequential therapy as first-line treatment for Helicobacter pylori infection in Korea: a retrospective study.

  Helicobacter 20100401

• Correlation of CYP2C19 genetic polymorphisms with helicobacter pylori eradication in patients with cirrhosis and peptic ulcer.

  Journal of the Chinese Medical Association : JCMA 20100401

• Esophageal mucosal injury with low-dose aspirin and its prevention by rabeprazole.

  Journal of clinical pharmacology 20100301

• Rabeprazole combined with hydrotalcite is effective for patients with bile reflux gastritis after cholecystectomy.

  Canadian journal of gastroenterology = Journal canadien de gastroenterologie 20100301

• Rabeprazole 20 mg for erosive esophagitis-associated symptoms in a large, community-based study: additional results.

  Digestive diseases and sciences 20100201

• Sleep dysfunction in Japanese patients with gastroesophageal reflux disease: prevalence, risk factors, and efficacy of rabeprazole.

  Digestion 20100101

• Improved HPLC method for determination of four PPIs, omeprazole, pantoprazole, lansoprazole and rabeprazole in human plasma.

  Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques 20100101

• Liquid chromatography-tandem mass/mass spectrometry method for the quantification of rabeprazole in human plasma and application to a pharmacokinetic study.

  Arzneimittel-Forschung 20100101

• Clopidogrel and proton pump inhibitor (PPI) interaction: separate intake and a non-omeprazole PPI the solution?

  European journal of medical research 20100101

• Characteristics of symptomatic reflux episodes in patients with non-erosive reflux disease who have a positive symptom index on proton pump inhibitor therapy.

  Digestion 20100101

• Immunoglobulin E-mediated anaphylaxis to rabeprazole.

  Journal of investigational allergology & clinical immunology 20100101

• Bioequivalence study of a fixed dose combination tablet containing rabeprazole and diclofenac sodium in healthy Indian subjects.

  Arzneimittel-Forschung 20100101

• Spectrophotometric determination of peptic ulcer sulfur-containing drugs in bulk form and in tablets.

  Drug testing and analysis 20100101

• Relationship between the acid-inhibitory effects of two proton pump inhibitors and CYP2C19 genotype in Japanese subjects: a randomized two-way crossover study.

  The Journal of international medical research 20100101

• Stability-indicating TLC-densitometric method for estimation of dexrabeprazole and domperidone in pharmaceutical dosage form.

  Preparative biochemistry & biotechnology 20100101

• The dual therapy with 4 times daily dosing of rabeprazole and amoxicillin as the 3rd rescue regimen for eradication of H. pylori.

  Hepato-gastroenterology 20100101

• The modified sequential treatment regimen containing levofloxacin for Helicobacter pylori eradication in Turkey.

  Helicobacter 20091201

• Efficacy and safety of rabeprazole in non-steroidal anti-inflammatory drug-induced ulcer in Japan.

  World journal of gastroenterology 20091028

• Long-term treatment with proton pump inhibitor is associated with undesired weight gain.

  World journal of gastroenterology 20091014

• Significant increase of esophageal mucin secretion in patients with reflux esophagitis after healing with rabeprazole: its esophagoprotective potential.

  Digestive diseases and sciences 20091001

• Systematic review: standard- and double-dose proton pump inhibitors for the healing of severe erosive oesophagitis -- a mixed treatment comparison of randomized controlled trials.

  Alimentary pharmacology & therapeutics 20090915

• [Long-term impact on quality of life in patients with gastroesophageal reflux disease after 52-week rabeprazole treatment].

  Zhonghua yi xue za zhi 20090915

• Comparison of one-week and two-week empirical trial with a high-dose rabeprazole in non-cardiac chest pain patients.

  Journal of gastroenterology and hepatology 20090901

• Is longer duration of proton pump inhibitor trial better for gastroesophageal reflux disease-related non-cardiac chest pain?

  Journal of gastroenterology and hepatology 20090901

• The effect of acid suppression on upper airway anatomy and obstruction in patients with sleep apnea and gastroesophageal reflux disease.

  Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine 20090815

• Long-term use of proton pump inhibitors: are they really safe? A case of delayed acute interstitial nephritis.

  Journal of the American Geriatrics Society 20090801

• Rabeprazole: a review of its use in the management of gastric acid-related diseases in adults.

  Drugs 20090709

• Simultaneous estimation of four proton pump inhibitors--lansoprazole, omeprazole, pantoprazole and rabeprazole: development of a novel generic HPLC-UV method and its application to clinical pharmacokinetic study.

  Biomedical chromatography : BMC 20090701

• Efficacy of a single 24-hour pre-anesthetic dose of proton pump inhibitors.

  Journal of gastroenterology and hepatology 20090701

• Management of acute peptic ulcers: how ethnicity, different proton pump inhibitors and mechanism of delivery alter the equation.

  Journal of gastroenterology and hepatology 20090701

• Comparison of p.o. or i.v. proton pump inhibitors on 72-h intragastric pH in bleeding peptic ulcer.

  Journal of gastroenterology and hepatology 20090701

• Interaction between clopidogrel and proton pump inhibitors.

  CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne 20090609

• Acute dyskinesia and extrapyramidal disorder in a child after ingestion of escitalopram.

  Journal of child and adolescent psychopharmacology 20090601

• Differential pulse polarographic investigation of lansoprazole and rabeprazole using dropping mercury electrode.

  Die Pharmazie 20090601

• Reflux profile of Chinese gastroesophageal reflux disease patients with combined multichannel intraluminal impedance-pH monitoring.

  Journal of gastroenterology and hepatology 20090601

• Identification of degradation products in stressed tablets of Rabeprazole sodium by HPLC-hyphenated techniques.

  Magnetic resonance in chemistry : MRC 20090501

• Clinical trial: the treatment of gastro-oesophageal reflux disease in primary care--prospective randomized comparison of rabeprazole 20 mg with esomeprazole 20 and 40 mg.

  Alimentary pharmacology & therapeutics 20090501

• Lack of modulation of gastric emptying by dietary nitrate in healthy volunteers.

  The Tohoku journal of experimental medicine 20090501

• Treatment of Schatzki's ring.

  Gastrointestinal endoscopy 20090501

• Pharmacokinetic- pharmacodynamic analysis of the role of CYP2C19 genotypes in short-term rabeprazole-based triple therapy against Helicobacter pylori.

  British journal of clinical pharmacology 20090501

• Increased health costs from mandated Therapeutic Substitution of proton pump inhibitors in British Columbia.

  Alimentary pharmacology & therapeutics 20090415

• Immediate acid-suppressing effects of ranitidine hydrochloride and rabeprazole sodium following initial administration and reintroduction: A randomized, cross-over study using wireless pH monitoring capsules.

  Journal of gastroenterology and hepatology 20090401

• Congenital absence of the splenic artery and splenic vein accompanied with a duodenal ulcer and deformity.

  World journal of gastroenterology 20090321

• The role of gastroesophageal reflux in exercise-triggered asthma: a randomized controlled trial.

  Digestive diseases and sciences 20090301

• Furazolidone, amoxicillin, bismuth and rabeprazole quadruple rescue therapy for the eradication of Helicobacter pylori.

  World journal of gastroenterology 20090221

• Does rabeprazole enhance distension-induced gastric accommodation?

  Digestive diseases and sciences 20090201

• The effect of gastroesophageal flap valve appearance on the management of patients with symptoms of gastroesophageal reflux disease.

  Digestive diseases and sciences 20090201

• Non-cardiac chest pain: prevalence of reflux disease and response to acid suppression in an Asian population.

  Journal of gastroenterology and hepatology 20090201

• A postmarketing surveillance study of dexrabeprazole in the treatment of acid peptic disorders.

  Journal of the Indian Medical Association 20090201

• Rabeprazole: a pharmacologic and clinical review for acid-related disorders.

  Expert opinion on drug safety 20090101

• A comparative study of proton-pump inhibitor tests for Chinese reflux patients in relation to the CYP2C19 genotypes.

  Journal of clinical gastroenterology 20090101

• Lack of in vitro interactions using human liver microsomes between rabeprazole and anticancer drugs.

  European journal of drug metabolism and pharmacokinetics 20090101

• In vitro antagonism of rabeprazole and metronidazole upon clinical isolates of Helicobacter pylori.

  Chemotherapy 20090101

• Little necessity of acid inhibition against proton pump inhibitor rebound effects and prior helicobacter pylori eradication therapy in gastric ulcer patients: a randomized prospective study.

  Hepato-gastroenterology 20090101

• High-performance thin-layer chromatographic determination of rabeprazole sodium and domperidone in combined dosage form.

  Journal of AOAC International 20090101

• Scoring of reflux symptoms associated with scleroderma and the usefulness of rabeprazole.

  Clinical and experimental rheumatology 20090101

• [Combined therapy of acid-dependent gastrointestinal disorders with the use of antacidic drug Relcer].

  Klinicheskaia meditsina 20090101

• Geranylgeranylacetone protects against diclofenac-induced gastric and small intestinal mucosal injuries in healthy subjects: a prospective randomized placebo-controlled double-blind cross-over study.

  Digestion 20090101

• Pharmacokinetics and bioequivalence study of a fixed dose combination of rabeprazole and itopride in healthy Indian volunteers.

  Arzneimittel-Forschung 20090101

• Absence of influence of concomitant administration of rabeprazole on the pharmacokinetics of tacrolimus in adult living-donor liver transplant patients: a case-control study.

  Drug metabolism and pharmacokinetics 20090101

• Spectrofluorometry, thin layer chromatography, and column high-performance liquid chromatography determination of rabeprazole sodium in the presence of its acidic and oxidized degradation products.

  Journal of AOAC International 20090101

• Negative chronotropic effect of proton pump inhibitors on frog-heart preparation.

  Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology 20090101

• [The quality of life dynamics in patients with gastroesophageal reflux disease during rabeprazol therapy].

  Eksperimental'naia i klinicheskaia gastroenterologiia = Experimental & clinical gastroenterology 20090101

• It is possible to classify non-erosive reflux disease (NERD) patients into endoscopically normal groups and minimal change groups by subjective symptoms and responsiveness to rabeprazole -- a report from a study with Japanese patients.

  Digestive diseases and sciences 20081201

• A glass of water immediately increases gastric pH in healthy subjects.

  Digestive diseases and sciences 20081201

• Gatifloxacin-based triple therapy as a third-line regimen for Helicobacter pylori eradication.

  Journal of gastroenterology and hepatology 20081201

• [Efficacy of 4 kinds of triple strategy for Helicobacter pylori eradication].

  Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences 20081201

• Effect of CYP2C19 genetic polymorphisms on the efficacy of proton pump inhibitor-based triple therapy for Helicobacter pylori eradication: a meta-analysis.

  Helicobacter 20081201

• Failure of Helicobacter pylori treatment after regimes containing clarithromycin: new practical therapeutic options.

  Helicobacter 20081201

• [Proton pump inhibition: more than only reflux therapy].

  MMW Fortschritte der Medizin 20081113

• Rabeto plus: a valuable drug for managing functional dyspepsia.

  Journal of the Indian Medical Association 20081101

• [Rabeprazole induced acute interstitial nephritis].

  La Revue de medecine interne 20081001

• [General practitioners' management of gastroesophageal reflux in France in 2005: a pharmacoeconomic study].

  Presse medicale (Paris, France : 1983) 20081001

• High performance liquid chromatographic analysis of rabeprazole in human plasma and its pharmacokinetic application.

  Archives of pharmacal research 20080901

• [Effect of Helicobacter pylori eradication on patients with functional dyspepsia].

  Revista espanola de enfermedades digestivas : organo oficial de la Sociedad Espanola de Patologia Digestiva 20080901

• Proton pump inhibitors may increase the risk of delayed bleeding complications after open heart surgery if used concomitantly with warfarin.

  The Thoracic and cardiovascular surgeon 20080801

• Rabeprazole: a second-generation proton pump inhibitor in the treatment of acid-related disease.

  Expert review of gastroenterology & hepatology 20080801

• [Comparison of Helicobacter pylori eradication rate in patients with non-ulcer dyspepsia and peptic ulcer diseases according to proton pump inhibitors].

  The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi 20080801

• Ten mg dexrabeprazole daily is as effective as 20 mg dexrabeprazole daily.

  World journal of gastroenterology 20080728

• Simple quantification of lansoprazole and rabeprazole concentrations in human serum by liquid chromatography/tandem mass spectrometry.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20080701

• Acid reflux detection and symptom-reflux association using 4-day wireless pH recording combining 48-hour periods off and on PPI therapy.

  The American journal of gastroenterology 20080701

• Quantitative analysis of rabeprazole sodium in commercial dosage forms by spectrophotometry.

  Chemical & pharmaceutical bulletin 20080701

• Chemometric determination of rabeprazole sodium in presence of its acid induced degradation products using spectrophotometry, polarography and anodic voltammetry at a glassy carbon electrode.

  Pakistan journal of pharmaceutical sciences 20080701

• Gastroesophageal reflux disease as an etiology of sleep disturbance in subjects with insomnia and minimal reflux symptoms: a pilot study of prevalence and response to therapy.

  Digestive diseases and sciences 20080601

• Response rate and predictors of response in a short-term empirical trial of high-dose rabeprazole in patients with globus.

  Alimentary pharmacology & therapeutics 20080601

• Quadruple rescue therapy for Helicobacter pylori infection after two treatment failures.

  European journal of clinical investigation 20080601

• Intramolecular nonbonded S...N interaction in rabeprazole.

  Chemical & pharmaceutical bulletin 20080601

• A randomized, prospective trial of electrosurgical incision followed by rabeprazole versus bougie dilation followed by rabeprazole of symptomatic esophageal (Schatzki's) rings.

  Gastrointestinal endoscopy 20080501

• Semipreparative chiral supercritical fluid chromatography in the fractionation of lansoprazole and two related antiulcer drugs enantiomers.

  Journal of separation science 20080501

• Recognizing doxycycline-induced esophageal ulcers in dental practice: a case report and review.

  Journal of the American Dental Association (1939) 20080501

• Is the required therapeutic effect always achieved by racemic switch of proton-pump inhibitors?

  World journal of gastroenterology 20080428

• Early effects of Lansoprazole orally disintegrating tablets on intragastric pH in CYP2C19 extensive metabolizers.

  World journal of gastroenterology 20080407

• Plasma concentration of rabeprazole after 8-week administration in gastroesophageal reflux disease patients and intragastric pH elevation.

  Journal of gastroenterology and hepatology 20080401

• Endoscopic analysis of gastric ulcer after one week's treatment with omeprazole and rabeprazole in relation to CYP2C19 genotype.

  Digestive diseases and sciences 20080401

• Upper gastrointestinal bleeding in patients with acute coronary syndromes: clinical predictors and prophylactic role of proton pump inhibitors.

  Journal of clinical gastroenterology 20080401

• HPTLC determination of rabeprazole and domperidone in capsules and its validation.

  Journal of chromatographic science 20080401

• Rabeprazole plus domperidone: the answer for gastro-oesophageal reflux disease.

  Journal of the Indian Medical Association 20080401

• Rapid protection of the gastroduodenal mucosa against aspirin-induced damage by rabeprazole.

  Alimentary pharmacology & therapeutics 20080315

• The influence of co-morbid IBS and psychological distress on outcomes and quality of life following PPI therapy in patients with gastro-oesophageal reflux disease.

  Alimentary pharmacology & therapeutics 20080315

• Spectrophotometric simultaneous determination of rabeprazole sodium and itopride hydrochloride in capsule dosage form.

  Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy 20080301

• In vitro metabolic stability of moisture-sensitive rabeprazole in human liver microsomes and its modulation by pharmaceutical excipients.

  Archives of pharmacal research 20080301

• Application of instrumental evaluation of color for the pre-formulation and formulation of rabeprazole.

  International journal of pharmaceutics 20080227

• Effect of pharmaceutical excipients on aqueous stability of rabeprazole sodium.

  International journal of pharmaceutics 20080227

• Long-term proton pump inhibitor use in children: a retrospective review of safety.

  Digestive diseases and sciences 20080201

• Proton pump inhibitors relieve and prevent symptoms related to gastric acidity after esophagectomy.

  World journal of surgery 20080201

• Evaluation of three different proton pump inhibitors with amoxicillin and metronidazole in retreatment for Helicobacter pylori infection.

  Journal of clinical gastroenterology 20080201

• Influence of lansoprazole and rabeprazole on mycophenolic acid pharmacokinetics one year after renal transplantation.

  Therapeutic drug monitoring 20080201

• Effect of single oral dose of sodium rabeprazole on the intragastric pH & volume in patients undergoing elective surgery.

  The Indian journal of medical research 20080201

• Structural elucidation of rabeprazole sodium photodegradation products.

  Journal of pharmaceutical and biomedical analysis 20080107

• Preoperative versus postoperative Helicobacter pylori eradication therapy in gastric cancer patients: a randomized trial.

  The American journal of gastroenterology 20080101

• High-performance liquid chromatography and thin-layer chromatography for the simultaneous quantitation of rabeprazole and mosapride in pharmaceutical products.

  Journal of chromatographic science 20080101

• Stereoselective disposition of proton pump inhibitors.

  Clinical drug investigation 20080101

• Interaction between tacrolimus and lansoprazole, but not rabeprazole in living-donor liver transplant patients with defects of CYP2C19 and CYP3A5.

  Drug metabolism and pharmacokinetics 20080101

• Column reversed-phase high-performance liquid chromatographic method for simultaneous determination of rabeprazole sodium and domperidone in combined tablet dosage form.

  Journal of AOAC International 20080101

• Time esophageal pH < 4 overestimates the prevalence of pathologic esophageal reflux in subjects with gastroesophageal reflux disease treated with proton pump inhibitors.

  BMC gastroenterology 20080101

• Evaluation of upper abdominal symptoms using the Frequency Scale for the Symptoms of Gastroesophageal Reflux Disease in patients with laryngopharyngeal reflux symptoms.

  Journal of gastroenterology 20080101

• No relationship between plasma desacyl-ghrelin levels and rabeprazole-related delay in gastric emptying : controlled study in healthy volunteers.

  Drugs in R&D 20080101

• Prokinetics influence the pharmacokinetics of rabeprazole.

  Digestion 20080101

• Effect of proton pump inhibitors on gastric juice volume, gastric pH and gastric intramucosal pH in critically ill patients : a randomized, double-blind, placebo-controlled study.

  Clinical drug investigation 20080101

• [The first results of the program Effective Eradication in Novosibirsk].

  Eksperimental'naia i klinicheskaia gastroenterologiia = Experimental & clinical gastroenterology 20080101

• Oral proton pump inhibitors are as effective as endoscopic treatment for bleeding peptic ulcer: a prospective, randomized, controlled trial.

  Digestive diseases and sciences 20071201

• Rabeprazole- versus esomeprazole-based eradication regimens for H. pylori infection.

  Helicobacter 20071201

• Double-dose, new-generation proton pump inhibitors do not improve Helicobacter pylori eradication rate.

  Helicobacter 20071201

• Maintenance treatment of gastroesophageal reflux disease: an evaluation of continuous and on-demand therapy with rabeprazole 20 mg.

  Canadian journal of gastroenterology = Journal canadien de gastroenterologie 20071201

• Distinct effects of omeprazole and rabeprazole on the tacrolimus blood concentration in a kidney transplant recipient.

  Drug metabolism and pharmacokinetics 20071201

• Gene expression changes of inflammatory mediators in posterior laryngitis due to laryngopharyngeal reflux and evolution with PPI treatment: a preliminary study.

  The Laryngoscope 20071101

• Levofloxacin-based triple therapy for Helicobacter pylori re-treatment: role of bacterial resistance.

  Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver 20071101

• Rabeprazole delays gastric emptying of a nutrient liquid.

  Journal of gastroenterology and hepatology 20071101

• Failures in a proton pump inhibitor therapeutic substitution program: lessons learned.

  Digestive diseases and sciences 20071001

• Comparison of four proton pump inhibitors for the short-term treatment of esophagitis in elderly patients.

  World journal of gastroenterology 20070907

• Preparative chiral chromatography and chiroptical characterization of enantiomers of omeprazole and related benzimidazoles.

  Chirality 20070901

• Helicobacter pylori eradication with either quadruple regimen with lactoferrin or levofloxacin-based triple therapy: a multicentre study.

  Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver 20070901

• CYP2C19 pharmacogenomics associated with therapy of Helicobacter pylori infection and gastro-esophageal reflux diseases with a proton pump inhibitor.

  Pharmacogenomics 20070901

• Pharmacokinetics and tolerability of rabeprazole sodium in subjects aged 12 to 16 years with gastroesophageal reflux disease: an open-label, single- and multiple-dose study.

  Clinical therapeutics 20070901

• Randomized, double-blind, comparative study of dexrabeprazole 10 mg versus rabeprazole 20 mg in the treatment of gastroesophageal reflux disease.

  World journal of gastroenterology 20070814

• Effect of a proton pump inhibitor or an H2-receptor antagonist on prevention of bleeding from ulcer after endoscopic submucosal dissection of early gastric cancer: a prospective randomized controlled trial.

  The American journal of gastroenterology 20070801

• Influence of cytochrome P450 2C19 genetic polymorphism and dosage of rabeprazole on accuracy of proton-pump inhibitor testing in Chinese patients with gastroesophageal reflux disease.

  Journal of gastroenterology and hepatology 20070801

• Dual therapy with high doses of rabeprazole and amoxicillin versus triple therapy with rabeprazole, amoxicillin, and metronidazole as a rescue regimen for Helicobacter pylori infection after the standard triple therapy.

  European journal of clinical pharmacology 20070801

• Recent advances in chirally pure proton pump inhibitors.

  Journal of the Indian Medical Association 20070801

• Proton pump inhibitors improve acid-related dyspepsia in gastroesophageal reflux disease patients.

  Digestive diseases and sciences 20070701

• Efficacy of rabeprazole on heartburn symptom resolution in patients with non-erosive and erosive gastro-oesophageal reflux disease: a multicenter study from Japan.

  Alimentary pharmacology & therapeutics 20070701

• Rabeprazole and psychiatric symptoms.

  The Annals of pharmacotherapy 20070701

• Effect of esomeprazole and rabeprazole on intragastric pH in healthy Chinese: an open, randomized crossover trial.

  Journal of gastroenterology and hepatology 20070601

• [Oesophageal acid exposure test in non-erosive gastroesophageal reflux disease and the diagnostic value of rabeprazole].

  Zhonghua nei ke za zhi 20070601

• Case of paroxysmal atrial fibrillation improved after the administration of proton pump inhibitor for associated reflux esophagitis.

  Fukuoka igaku zasshi = Hukuoka acta medica 20070601

• Influence of rabeprazole and lansoprazole on the pharmacokinetics of tacrolimus in relation to CYP2C19, CYP3A5 and MDR1 polymorphisms in renal transplant recipients.

  Biopharmaceutics & drug disposition 20070501

• Liquid chromatographic-mass spectrometry analysis and pharmacokinetic studies of a novel rabeprazole formulation, sterile powder for injection, in dogs and rats.

  Biopharmaceutics & drug disposition 20070501

• Rabeprazole-based eradication therapy for Helicobacter pylori: a large-scale study in Japan.

  Alimentary pharmacology & therapeutics 20070501

• Prediction of gastroesophageal reflux in otitis media with effusion in adults.

  Acta oto-laryngologica 20070501

• Pattern of proton pump inhibitor calls to Texas poison centers, 1998-2004.

  Journal of toxicology and environmental health. Part A 20070415

• [Clinical pharmacological aspects of the proton pump inhibitor therapy: importance of pharmacogenetic differences in the clinical practice].

  Orvosi hetilap 20070325

• Programme of stepping down from twice daily proton pump inhibitor therapy for symptomatic gastro-oesophageal reflux disease associated with a formulary change at a VA medical center.

  Alimentary pharmacology & therapeutics 20070315

• Identification and characterization of potential impurities of rabeprazole sodium.

  Journal of pharmaceutical and biomedical analysis 20070312

• Efficacy of low-dose proton pump inhibitor (PPI) in the eradication of Helicobacter pylori following combination PPI/AC therapy in Japan.

  Hepato-gastroenterology 20070301

• Combined analysis of three crossover clinical pharmacology studies of effects of rabeprazole and esomeprazole on 24-h intragastric pH in healthy volunteers.

  Alimentary pharmacology & therapeutics 20070215

• Pharmacodynamic effects of single doses of rabeprazole 20 mg and pantoprazole 40 mg in patients with GERD and nocturnal heartburn.

  Alimentary pharmacology & therapeutics 20070215

• Comparative drug effects: the case of GERD therapies.

  Disease management : DM 20070201

• Kinetics of decomposition of rabeprazole sodium in aqueous solutions determined by high performance liquid chromatography.

  Die Pharmazie 20070201

• Gastric mucosal levels of prostaglandins and leukotrienes in patients with gastric ulcer after treatment with rabeprazole in comparison to treatment with ranitidine.

  The journal of medical investigation : JMI 20070201

• [Helicobacter pylori erradication and its relation to antibiotic resistance and CYP2C19 status].

  Revista espanola de enfermedades digestivas : organo oficial de la Sociedad Espanola de Patologia Digestiva 20070201

• Use of proton pump inhibitors may cause squamous epithelial masking of intramucosal carcinoma in Barrett's esophagus.

  Endoscopy 20070201

• A relapse case of acute necrotizing esophagitis.

  Endoscopy 20070201

• Simultaneous determination of rabeprazole sodium and itopride hydrochloride in capsule dosage form by spectrophotometry.

  Hindustan antibiotics bulletin 20070201

• Oral rabeprazole vs. intravenous pantoprazole: a comparison of the effect on intragastric pH in healthy subjects.

  Alimentary pharmacology & therapeutics 20070115

• Severe bradycardia in a stroke patient caused by a single low dose of escitalopram.

  European neurology 20070101

• [Pharmacological efficacy of bismuth tripotassium dicitrate in peptic ulcer].

  Terapevticheskii arkhiv 20070101

• [Rabeprazole test and comparison of the effectiveness of course treatment with rabeprazole in patients with gastroesophageal reflux disease and non-coronary chest pain].

  Klinicheskaia meditsina 20070101

• [The clinical effectiveness of rabeprazole in patients with acid-related gastric and duodenal diseases with various sensitivity of different types of parietal gastric cell receptors].

  Klinicheskaia meditsina 20070101

• Comparative study of proton pump inhibitors for triple therapy in H. pylori eradication.

  Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology 20070101

• The papilla of Vater just below the pylorus presenting as recurrent duodenal ulcer bleeding.

  Internal medicine (Tokyo, Japan) 20070101

• [Clinical course of Helicobacter pylori associated chronic gastritis in post-eradicational period].

  Eksperimental'naia i klinicheskaia gastroenterologiia = Experimental & clinical gastroenterology 20070101

• [Safety of proton pump inhibitors].

  Medicina clinica 20061125

• [Reflux esophagitis. Step-down instead of step-up].

  MMW Fortschritte der Medizin 20061123

• A comparative study of intragastric acidity during post-breakfast and pre-dinner administration of low-dose proton pump inhibitors: a randomized three-way crossover study.

  Alimentary pharmacology & therapeutics 20061115

• An open-label study of rabeprazole in patients with Zollinger-Ellison syndrome or idiopathic gastric acid hypersecretion.

  Alimentary pharmacology & therapeutics 20061115

• Liquid chromatographic/mass spectrometric assay of rabeprazole in dog plasma for a pharmacokinetic study.

  Biomedical chromatography : BMC 20061101

• Acid-suppressive effects of rabeprazole: comparing 10mg and 20mg twice daily in Japanese Helicobacter pylori-negative and -positive CYP2C19 extensive metabolisers.

  Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver 20061101

• Pharmacodynamic studies on PPIs: look carefully at the country of origin.

  Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver 20061101

• Influence of acid suppressants on gastric emptying: cross-over analysis in healthy volunteers.

  Journal of gastroenterology and hepatology 20061101

• Mass balance study of [14C] rabeprazole following oral administration in healthy subjects.

  International journal of clinical pharmacology and therapeutics 20061101

• Identification of the time-point which gives a plasma rabeprazole concentration that adequately reflects the area under the concentration-time curve.

  European journal of clinical pharmacology 20061001

• Effect of a proton pump inhibitor on postprandial gastric volume, emptying and symptoms in healthy human subjects: a pilot study.

  Alimentary pharmacology & therapeutics 20061001

• Effect of rabeprazole and omeprazole on the onset of gastro-oesophageal reflux disease symptom relief during the first seven days of treatment.

  Scandinavian journal of gastroenterology 20061001

• Does Helicobacter pylori infection influence response rate or speed of symptom control in patients with gastroesophageal reflux disease treated with rabeprazole?

  Scandinavian journal of gastroenterology 20061001

• Effects of single doses of rabeprazole 20 mg and esomeprazole 40 mg on 24-h intragastric pH in healthy subjects.

  European journal of clinical pharmacology 20060901

• Comparison of the efficacy of rabeprazole 10 mg and omeprazole 20 mg for the healing rapidity of peptic ulcer diseases.

  Journal of gastroenterology and hepatology 20060901

• Therapeutic effects of 10 mg/day rabeprazole administration on reflux esophagitis was not influenced by the CYP2C19 polymorphism.

  Journal of gastroenterology and hepatology 20060901

• Systematic review: proton pump inhibitors (PPIs) for the healing of reflux oesophagitis - a comparison of esomeprazole with other PPIs.

  Alimentary pharmacology & therapeutics 20060901

• Monitoring cytochrome P-450 activity during rabeprazole treatment in patients with gastresophageal reflux disease.

  Digestive diseases and sciences 20060901

• Effect of esophageal acid and prophylactic rabeprazole on performance in runners.

  Medicine and science in sports and exercise 20060901

• 14-day quadruple therapy with ranitidine bismuth citrate after Helicobacter pylori treatment failure in Thailand.

  Journal of the Medical Association of Thailand = Chotmaihet thangphaet 20060901

• Pharmacodynamic and kinetic effect of rabeprazole on serum gastrin level in relation to CYP2C19 polymorphism in Chinese Hans.

  World journal of gastroenterology 20060807

• Effects of clarithromycin and verapamil on rabeprazole pharmacokinetics between CYP2C19 genotypes.

  European journal of clinical pharmacology 20060801

• Efficacy and safety of rabeprazole, amoxicillin, and gatifloxacin after treatment failure of initial Helicobacter pylori eradication.

  Helicobacter 20060801

• Effects of sucralfate, cimetidine and rabeprazole on mucosal hydroxyproline content in healing of ethanol-hcl-induced gastric lesions.

  Clinical and experimental pharmacology & physiology 20060701

• Can Helicobacter pylori eradication regimens be shortened in clinical practice? An open-label, randomized, pilot study of 4 and 7-day triple therapy with rabeprazole, high-dose levofloxacin, and tinidazole.

  Journal of clinical gastroenterology 20060701

• The effect of CYP2C19 polymorphisms on H. pylori eradication rate in dual and triple first-line PPI therapies: a meta-analysis.

  The American journal of gastroenterology 20060701

• Effects of rabeprazole or famotidine during cardiac surgery on perioperative gastric and esophageal pH readings.

  The Japanese journal of thoracic and cardiovascular surgery : official publication of the Japanese Association for Thoracic Surgery = Nihon Kyobu Geka Gakkai zasshi 20060701

• Development and validation of a dissolution test for rabeprazole sodium in coated tablets.

  Journal of pharmaceutical and biomedical analysis 20060607

• Enantioselective disposition of lansoprazole and rabeprazole in human plasma.

  Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan 20060601

• Myopathy including polymyositis: a likely class adverse effect of proton pump inhibitors?

  European journal of clinical pharmacology 20060601

• Effect of a therapeutic maximum allowable cost (MAC) program on the cost and utilization of proton pump inhibitors in an employer-sponsored drug plan in Canada.

  Journal of managed care pharmacy : JMCP 20060601

• Sub-optimal proton pump inhibitor dosing is prevalent in patients with poorly controlled gastro-oesophageal reflux disease.

  Alimentary pharmacology & therapeutics 20060515

• Determination of rabeprazole enantiomers and their metabolites by high-performance liquid chromatography with solid-phase extraction.

  Journal of pharmaceutical and biomedical analysis 20060503

• Microsphere-based protease assays and screening application for lethal factor and factor Xa.

  Cytometry. Part A : the journal of the International Society for Analytical Cytology 20060501

• Proton pump inhibitors and acute interstitial nephritis.

  Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association 20060501

• Rabeprazole test for the diagnosis of gastro-oesophageal reflux disease: results of a study in a primary care setting.

  World journal of gastroenterology 20060428

• Comparison of the effects of proton pump inhibitors on human plasma adrenocorticotropic hormone and cortisol levels under the starved condition.

  Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 20060401

• A therapeutic substitution policy for proton pump inhibitors: clinical and economic consequences.

  Clinical pharmacology and therapeutics 20060401

• The effects of changing temperature correction factors on measures of acidity calculated from gastric and oesophageal pH recordings.

  Alimentary pharmacology & therapeutics 20060301

• Review article: the role of acid suppression in patients with non-erosive reflux disease or functional heartburn.

  Alimentary pharmacology & therapeutics 20060301

• Different effects of fluvoxamine on rabeprazole pharmacokinetics in relation to CYP2C19 genotype status.

  British journal of clinical pharmacology 20060301

• Enantioselective disposition of rabeprazole in relation to CYP2C19 genotypes.

  British journal of clinical pharmacology 20060301

• Hypersensitivity to lansoprazole and rabeprazole with tolerance to other proton pump inhibitors.

  The Journal of allergy and clinical immunology 20060301

• Proton pump inhibitor therapy in atazanavir-treated patients: contraindicated?

  Journal of acquired immune deficiency syndromes (1999) 20060301

• Stereoselective metabolism of rabeprazole-thioether to rabeprazole by human liver microsomes.

  European journal of clinical pharmacology 20060201

• Pharmacokinetics of three proton pump inhibitors in Chinese subjects in relation to the CYP2C19 genotype.

  European journal of clinical pharmacology 20060201

• Clarithromycin-resistant genotypes and eradication of Helicobacter pylori.

  Annals of internal medicine 20060117

• A study of 4- and 7-day triple therapy with rabeprazole, high-dose levofloxacin and tinidazole rescue treatment for Helicobacter pylori eradication.

  Alimentary pharmacology & therapeutics 20060115

• Rabeprazole containing triple therapy to eradicate Helicobacter pylori infection on the Texas-Mexican border.

  Alimentary pharmacology & therapeutics 20060115

• Acid-suppressive effects of rabeprazole, omeprazole, and lansoprazole at reduced and standard doses: a crossover comparative study in homozygous extensive metabolizers of cytochrome P450 2C19.

  Clinical pharmacology and therapeutics 20060101

• [A randomized, prospective, comparative, multicenter study of rabeprazole and ranitidine in the treatment of reflux esophagitis].

  The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi 20060101

• Efficacy of a proton pump inhibitor given in the early postoperative period to relieve symptoms of hiatal hernia after open heart surgery.

  Surgery today 20060101

• Effectiveness of minocycline-based triple therapy for eradication of Helicobacter pylori infection.

  Journal of gastroenterology and hepatology 20060101

• 'Best practice' for Helicobacter pylori eradication in the primary care setting.

  Irish medical journal 20060101

• Pharmacokinetic and pharmacodynamic population modeling of orally administered rabeprazole in healthy Chinese volunteers by the NONMEM method.

  European journal of drug metabolism and pharmacokinetics 20060101

• Update on clarithromycin resistance in Helicobacter pylori in Hong Kong and its effect on clarithromycin-based triple therapy.

  Digestion 20060101

• [Symptomatic high chromogranin A level associated with rabeprazole and ranitidine].

  Therapie 20060101

• Comparison of the effects of single and repeated oral doses of lansoprazole and rabeprazole on ambulatory 24-hour intragastric pH in healthy volunteers.

  Clinical drug investigation 20060101

• [Rabeprazole in the treatment of acid-dependent diseases in children].

  Eksperimental'naia i klinicheskaia gastroenterologiia = Experimental & clinical gastroenterology 20060101

• Cryoablation of Barrett's esophagus: a pilot study.

  Gastrointestinal endoscopy 20051201

• Rabeprazole: the role of proton pump inhibitors in Helicobacter pylori eradication.

  Expert review of anti-infective therapy 20051201

• Rabeprazole experience in Korea; focus on CYP2C19 polymorphism.

  Journal of gastroenterology and hepatology 20051201

• CYP2C19 genotype and the PPIs--focus on rabeprazole.

  Journal of gastroenterology and hepatology 20051201

• Efficacy of Helicobacter pylori eradication on the chronic mucosal inflammation of the remnant stomach after distal gastrectomy for early gastric cancer.

  Journal of experimental & clinical cancer research : CR 20051201

• Idiopathic pure red cell aplasia: case report with review of literature.

  South Dakota journal of medicine 20051201

• Efficacy of rabeprazole in the treatment of symptomatic gastroesophageal reflux disease.

  Digestive diseases and sciences 20051101

• Development and validation of the Gastroesophageal Reflux Disease Treatment Satisfaction Questionnaire.

  Digestive diseases and sciences 20051101

• Four-day Bravo pH capsule monitoring with and without proton pump inhibitor therapy.

  Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association 20051101

• [The impact of rabeprazole treatment on the quality of life in patients with reflux esophagitis and non-erosive reflux disease].

  Zhonghua nei ke za zhi 20051101

• Identification and synthesis of potential impurities of rabeprazole sodium.

  Die Pharmazie 20051101

• [Establishment of 2nd line treatment regimen for H. pylori infection--future prospect for the application for national health insurance system in Japan].

  Nihon rinsho. Japanese journal of clinical medicine 20051101

• [Recent topics on important drugs for H. pylori eradication: Rabeprazole].

  Nihon rinsho. Japanese journal of clinical medicine 20051101

• [Second-line eradication therapy for H. pylori infection--PPI+AMPC+MNZ triple therapy].

  Nihon rinsho. Japanese journal of clinical medicine 20051101

• [High dose dual PPI/AMPC therapy for the treatment of Helicobacter pylori infection after failure of usual standard triple PPI/AMPC/CAM therapy].

  Nihon rinsho. Japanese journal of clinical medicine 20051101

• [Investigation about 3rd line eradication of H. pylori].

  Nihon rinsho. Japanese journal of clinical medicine 20051101

• Rabeprazole is equivalent to omeprazole in the treatment of erosive gastro-oesophageal reflux disease. A randomised, double-blind, comparative study of rabeprazole and omeprazole 20 mg in acute treatment of reflux oesophagitis, followed by a maintenance open-label, low-dose therapy with rabeprazole.

  Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver 20051001

• Lack of predictors of normalization of oesophageal acid exposure in Barrett's oesophagus.

  Alimentary pharmacology & therapeutics 20051001

• Dysphagia associated with gastroesophageal reflux disease is improved by proton pump inhibitor.

  Digestive diseases and sciences 20051001

• The efficacy of preanesthetic proton pump inhibitor treatment for patients on long-term H2 antagonist therapy.

  Anesthesia and analgesia 20051001

• Cost-effectiveness comparison of current proton-pump inhibitors to treat gastro-oesophageal reflux disease in the UK.

  Current medical research and opinion 20051001

• Determination of rabeprazole and its active metabolite, rabeprazole thioether in human plasma by column-switching high-performance liquid chromatography and its application to pharmacokinetic study.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20050925

• The effect of a therapeutic trial of high-dose rabeprazole on symptom response of patients with non-cardiac chest pain: a randomized, double-blind, placebo-controlled, crossover trial.

  Alimentary pharmacology & therapeutics 20050915

• Control of intra-oesophageal and intra-gastric pH with proton pump inhibitors in patients with Barrett's oesophagus.

  Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver 20050901

• A comparative study on endoscopic ulcer healing of omeprazole versus rabeprazole with respect to CYP2C19 genotypic differences.

  Digestive diseases and sciences 20050901

• Allergy to lansoprazole: study of cross-reactivity among proton-pump inhibitors.

  Allergy 20050801

• Seven versus ten days of rabeprazole triple therapy for Helicobacter pylori eradication: a multicenter randomized trial.

  The American journal of gastroenterology 20050801

• Long-term prevention of erosive or ulcerative gastro-oesophageal reflux disease relapse with rabeprazole 10 or 20 mg vs. placebo: results of a 5-year study in the United States.

  Alimentary pharmacology & therapeutics 20050801

• Acid-suppressive efficacy of a reduced dosage of rabeprazole: comparison of 10 mg twice daily rabeprazole with 20 mg twice daily rabeprazole, 30 mg twice daily lansoprazole, and 20 mg twice daily omeprazole by 24-hr intragastric pH-metry.

  Digestive diseases and sciences 20050701

• Influence of 1-week Helicobacter pylori eradication therapy with rabeprazole, clarithromycin, and metronidazole on 13C-aminopyrine breath test.

  Digestive diseases and sciences 20050701

• Effects of antisecretory agents on angiogenesis during healing of gastric ulcers.

  Journal of gastroenterology 20050701

• High rate of Helicobacter pylori eradication with sequential therapy in elderly patients with peptic ulcer: a prospective controlled study.

  Alimentary pharmacology & therapeutics 20050615

• Air swallowing can be responsible for non-response of heartburn to high-dose proton pump inhibitor.

  Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver 20050601

• Proton pump inhibitors: update on their role in acid-related gastrointestinal diseases.

  International journal of clinical practice 20050601

• The effect of rabeprazole on regional gastric acidity and the postprandial cardia/gastro-oesophageal junction acid layer in normal subjects: a randomized, double-blind, placebo-controlled study.

  Alimentary pharmacology & therapeutics 20050601

• Low-dose rabeprazole, amoxicillin and metronidazole triple therapy for the treatment of Helicobacter pylori infection in Chinese patients.

  Journal of gastroenterology and hepatology 20050601

• Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies.

  Drug metabolism and pharmacokinetics 20050601

• Rabeprazole vs esomeprazole in non-erosive gastro-esophageal reflux disease: a randomized, double-blind study in urban Asia.

  World journal of gastroenterology 20050528

• Effects of 5 years of treatment with rabeprazole or omeprazole on the gastric mucosa.

  European journal of gastroenterology & hepatology 20050501

• [A randomized, comparative study of rabeprazole vs. ranitidine maintenance therapies for reflux esophagitis--multicenter study].

  The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi 20050501

• Rabeprazole controls GERD symptoms in a patient for whom treatment with lansoprazole failed: first report of 'cluster GERD.'.

  Digestive diseases and sciences 20050501

• Early effects of lafutidine or rabeprazole on intragastric acidity: which drug is more suitable for on-demand use?

  Journal of gastroenterology 20050501

• A new-generation H2 receptor antagonist: quicker and stronger acid inhibition than proton pump inhibitors in the clinical setting?

  Journal of gastroenterology 20050501

• Comparison of enantioselective disposition of rabeprazole versus lansoprazole in renal-transplant recipients who are CYP2C19 extensive metabolizers.

  Xenobiotica; the fate of foreign compounds in biological systems 20050501

• Long-term treatment of gastro-oesophageal reflux disease patients with frequent symptomatic relapses using rabeprazole: on-demand treatment compared with continuous treatment.

  Alimentary pharmacology & therapeutics 20050401

• Effects of rabeprazole on early symptom relief in gastro-oesophageal reflux disease: the Hellenic Rabeprazole Study Group surveillance study.

  Current medical research and opinion 20050401

• Comparison of an increased dosage regimen of rabeprazole versus a concomitant dosage regimen of famotidine with rabeprazole for nocturnal gastric acid inhibition in relation to cytochrome P450 2C19 genotypes.

  Clinical pharmacology and therapeutics 20050401

• [The clinical applications of rabeprazole either alone or combined with anti-Helicobacter pylori agents in peptic ulcer patients].

  Zhonghua nei ke za zhi 20050401

• Sofalcone, a mucoprotective agent, increases the cure rate of Helicobacter pylori infection when combined with rabeprazole, amoxicillin and clarithromycin.

  World journal of gastroenterology 20050321

• One-year follow-up study of Helicobacter pylori eradication rate with 13C-urea breath test after 3-d and 7-d rabeprazole-based triple therapy.

  World journal of gastroenterology 20050321

• New once-daily, highly effective rescue triple therapy after multiple Helicobacter pylori treatment failures: a pilot study.

  Alimentary pharmacology & therapeutics 20050315

• Pharmacodynamic effects and kinetic disposition of rabeprazole in relation to CYP2C19 genotype in healthy Chinese subjects.

  Acta pharmacologica Sinica 20050301

• Prospective randomized trial for optimal prophylactic treatment of the upper gastrointestinal complications after open heart surgery.

  Circulation journal : official journal of the Japanese Circulation Society 20050301

• Attenuating effect of H+K+ATPase inhibitors on airway cough hypersensitivity induced by allergic airway inflammation in guinea-pigs.

  Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology 20050301

• Cost effective prescribing of proton pump inhibitors (PPI's) in the GMS Scheme.

  Irish medical journal 20050301

• High-performance liquid chromatography method for the quantification of rabeprazole in human plasma using solid-phase extraction.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20050225

• Response of blood endothelin-1 and nitric oxide activity in duodenal ulcer patients undergoing Helicobacter pylori eradication.

  World journal of gastroenterology 20050221

• Amoxicillin resistance in Helicobacter pylori: studies from Tokyo, Japan from 1985 to 2003.

  Helicobacter 20050201

• Rabeprazole-induced acute interstitial nephritis.

  Nephrology (Carlton, Vic.) 20050201

• Restorative impact of rabeprazole on gastric mucus and mucin production impairment during naproxen administration: its potential clinical significance.

  Digestive diseases and sciences 20050201

• The effect of acid suppression on sleep patterns and sleep-related gastro-oesophageal reflux.

  Alimentary pharmacology & therapeutics 20050115

• Spillover effects of restrictive drug formularies: a case study of PacifiCare in California.

  The American journal of managed care 20050101

• Pharmacokinetics of rabeprazole following single intravenous and oral administration to healthy subjects.

  International journal of clinical pharmacology and therapeutics 20050101

• Proton pump inhibitors: a survey of prescribing in an Irish general hospital.

  International journal of clinical practice 20050101

• [Is anti-helicobacter therapy a rational approach in treatment of erosive and ulcerous lesions of the gastroduodenal mucosa in patients with inflamatory bowel diseases?].

  Klinicheskaia meditsina 20050101

• [Esomeprasol and rabeprasol effects on esophageal acidification in patients with gastroesophageal reflux disease, intensively metabolizing inhibitors of proton pump].

  Terapevticheskii arkhiv 20050101

• Efficacy of a triple therapy with rabeprazole, amoxicillin, and faropenem as second-line treatment after failure of initial Helicobacter pylori eradication therapy.

  Hepato-gastroenterology 20050101

• [Assessment of efficacy and safety of two modes of maintenance therapy with rabeprazole in patients with gastroesophageal reflux disease (GERD) of degrees 0 and 1].

  Eksperimental'naia i klinicheskaia gastroenterologiia = Experimental & clinical gastroenterology 20050101

• Development of a liquid chromatography/tandem mass spectrometry assay for the quantification of rabeprazole in human plasma.

  Rapid communications in mass spectrometry : RCM 20050101

• [Pharmacogenomical aspects of gastroesophageal reflux disease].

  Vestnik Rossiiskoi akademii meditsinskikh nauk 20050101

• Validation of a capillary electrophoresis method for analysis of rabeprazole sodium in a pharmaceutical dosage form.

  Journal of AOAC International 20050101

• Dual effects of rabeprazole on solid-phase gastric emptying assessed by the 13C-octanoate breath test.

  Digestion 20050101

• What is potent acid inhibition, and how can it be achieved?

  Drugs 20050101

• [Oral cavity manifestations of gastroesophageal reflux disease].

  Klinicheskaia meditsina 20050101

• [Utility of rabeprazole as a diagnostic test in non-erosive gastroesophageal reflux disease].

  Revista de gastroenterologia de Mexico 20050101

• [Results of the treatment of duodenal ulcer associated with Helicobacter pylori and combined with gastroesophageal reflux disease].

  Eksperimental'naia i klinicheskaia gastroenterologiia = Experimental & clinical gastroenterology 20050101

• Direct injection, column switching-liquid chromatographic technique for the estimation of rabeprazole in bioequivalence study.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20041225

• Frequency analyses of gastric pH in control and gastro-oesophageal reflux disease subjects treated with a proton-pump inhibitor.

  Alimentary pharmacology & therapeutics 20041201

• Bacteriostatic and bactericidal activity of rabeprazole against Helicobacter pylori.

  Journal of chemotherapy (Florence, Italy) 20041201

• The effect of rabeprazole alone or in combination with H2 receptor blocker on intragastric pH: a pilot study.

  The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology 20041201

• Bacillus clausii therapy to reduce side-effects of anti-Helicobacter pylori treatment: randomized, double-blind, placebo controlled trial.

  Alimentary pharmacology & therapeutics 20041115

• Review article: relationship between the metabolism and efficacy of proton pump inhibitors--focus on rabeprazole.

  Alimentary pharmacology & therapeutics 20041101

• Review article: relief of symptoms in gastric acid-related diseases--correlation with acid suppression in rabeprazole treatment.

  Alimentary pharmacology & therapeutics 20041101

• Review article: pH, healing and symptom relief with rabeprazole treatment in acid-related disorders.

  Alimentary pharmacology & therapeutics 20041101

• [Choice of proton pump inhibitors--does it play any role?].

  Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke 20041021

• Effect of low-dose rabeprazole and omeprazole on gastric acidity: results of a double blind, randomized, placebo-controlled, three-way crossover study in healthy subjects.

  Alimentary pharmacology & therapeutics 20041015

• Monocyte chemotactic protein-1 regulates leukocyte recruitment during gastric ulcer recurrence induced by tumor necrosis factor-alpha.

  American journal of physiology. Gastrointestinal and liver physiology 20041001

• Esomeprazole 40 mg provides more effective intragastric acid control than lansoprazole 30 mg, omeprazole 20 mg, pantoprazole 40 mg and rabeprazole 20 mg in patients with gastro-oesophageal reflux symptoms.

  European journal of clinical pharmacology 20041001

• Open, randomized multicenter comparative trial of rabeprazole, ofloxacin and amoxicillin therapy for Helicobacter pylori eradication: 7 vs. 14 day treatment.

  Helicobacter 20041001

• Improvement in clinical course and laryngeal appearance in selected patients with chronic laryngitis after eight weeks of therapy with rabeprazole.

  Medical science monitor : international medical journal of experimental and clinical research 20041001

• Effect of rabeprazole on MDR1-mediated transport of Rhodamine 123 in Caco-2 and Hvr100-6 cells.

  Biological & pharmaceutical bulletin 20041001

• Proton pump inhibitor therapy for chronic laryngo-pharyngitis: a randomized placebo-control trial.

  Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery 20041001

• Different dosage regimens of rabeprazole for nocturnal gastric acid inhibition in relation to cytochrome P450 2C19 genotype status.

  Clinical pharmacology and therapeutics 20041001

• [Five-day rabeprazole-based triple therapy for helicobacter pylori infection].

  Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences 20041001

• Review article: efficacy and safety of rabeprazole in treating gastroesophageal reflux disease.

  Journal of gastroenterology and hepatology 20040901

• Suppression of gastric acid production may improve the course of angina pectoris and the results of treadmill stress test in patients with coronary artery disease.

  Medical science monitor : international medical journal of experimental and clinical research 20040901

• [The effect of rabeprazole on gastric pH in patients with gastric ulcer].

  Zhonghua nei ke za zhi 20040901

• Results of triple eradication therapy in Japanese children: a retrospective multicenter study.

  Journal of gastroenterology 20040901

• Treatment of gastro-oesophageal reflux disease with rabeprazole in primary and secondary care: does Helicobacter pylori infection affect proton pump inhibitor effectiveness?

  Alimentary pharmacology & therapeutics 20040815

• Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities.

  Drug metabolism and disposition: the biological fate of chemicals 20040801

• Effect of lansoprazole and rabeprazole on tacrolimus pharmacokinetics in healthy volunteers with CYP2C19 mutations.

  The Journal of pharmacy and pharmacology 20040801

• [Primary care for GEDR].

  Nihon rinsho. Japanese journal of clinical medicine 20040801

• [Evaluation of the efficacy and the cost-effectiveness of maintenance treatment of gastroesophageal reflux disease: proton pump inhibitor versus histamine-2-receptor antagonist].

  Nihon rinsho. Japanese journal of clinical medicine 20040801

• [PPI: new strategies for GERD].

  Nihon rinsho. Japanese journal of clinical medicine 20040801

• Chiral separation of omeprazole and several related benzimidazoles using supercritical fluid chromatography.

  Journal of separation science 20040801

• Six-month trial of on-demand rabeprazole 10 mg maintains symptom relief in patients with non-erosive reflux disease.

  Alimentary pharmacology & therapeutics 20040715

• Seven-day therapy for Helicobacter pylori in the United States.

  Alimentary pharmacology & therapeutics 20040701

• Voltammetric behaviour of rabeprazole at a glassy carbon electrode and its determination in tablet dosage form.

  Farmaco (Societa chimica italiana : 1989) 20040701

• [Prospective comparative study on protective effect of the proton pump inhibitor and the prostaglandin analog on H. pylori-negative gastric mucosa of healthy subjects against low-dose aspirin].

  [Hokkaido igaku zasshi] The Hokkaido journal of medical science 20040701

• [New-generation proton pump inhibitors: progress in the treatment of peptic acid diseases?].

  Presse medicale (Paris, France : 1983) 20040619

• Efficacy of two rabeprazole/gatifloxacin-based triple therapies for Helicobacter pylori infection.

  Helicobacter 20040601

• Twice daily (mid-day and evening) quadruple therapy for H. pylori infection in the United States.

  Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver 20040601

• On-demand therapy with rabeprazole in nonerosive and erosive gastroesophageal reflux disease in clinical practice: effectiveness, health-related quality of life, and patient satisfaction.

  Digestive diseases and sciences 20040601

• Significance of non-erosive minimal esophageal lesions in gastro-esophageal reflux disorder.

  The Korean journal of internal medicine 20040601

• Health-related quality of life in patients with cardiovascular disease--the effect of upper gastrointestinal symptom treatment.

  Alimentary pharmacology & therapeutics 20040515

• Effectiveness and pharmaceutical cost of sequential treatment for Helicobacter pylori in patients with non-ulcer dyspepsia.

  Alimentary pharmacology & therapeutics 20040501

• Persistent acid and bile reflux in asymptomatic patients with Barrett esophagus receiving proton pump inhibitor therapy.

  Archives of surgery (Chicago, Ill. : 1960) 20040501

• The prolongation of triple therapy for Helicobacter pylori does not allow reaching therapeutic outcome of sequential scheme: a prospective, randomised study.

  Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver 20040501

• Helicobacter pylori eradication rate and glycemic control in young patients with type 1 diabetes.

  Journal of pediatric gastroenterology and nutrition 20040401

• Sequential treatment for Helicobacter pylori does not share the risk factors of triple therapy failure.

  Alimentary pharmacology & therapeutics 20040215

• The effect of eight weeks of rabeprazole therapy on nitric oxide plasma level and esophageal pH and motility and motility nitric oxide plasma level in patients with erosive esophagitis.

  Medical science monitor : international medical journal of experimental and clinical research 20040201

• High-dose versus low-dose clarithromycin in 1-week triple therapy, including rabeprazole and levofloxacin, for Helicobacter pylori eradication.

  Journal of clinical gastroenterology 20040201

• Cost-minimization analysis of treatment of gastroesophageal reflux disease. Implications of varying holding time on conclusions.

  European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences 20040201

• Review of rabeprazole in the treatment of gastro-oesophageal reflux disease.

  Expert opinion on pharmacotherapy 20040101

• Rabeprazole 10 mg twice daily is superior to 20 mg once daily for night-time gastric acid suppression.

  Alimentary pharmacology & therapeutics 20040101

• [Effect of CYP2C19 genetic polymorphism on treatment efficacy of Helicobacter pylori infection with rabeprazole-based triple therapy in Chinese].

  Zhonghua nei ke za zhi 20040101

• Bioequivalence study of rabeprazole sodium on healthy human volunteers.

  Journal of the Indian Medical Association 20040101

• Bioequivalence evaluation of two rabeprazole enteric coated formulations in healthy Chinese volunteers.

  European journal of drug metabolism and pharmacokinetics 20040101

• New liquid chromatographic method for determination of rabeprazole sodium in coated tablets.

  Journal of AOAC International 20040101

• Perforated duodenal ulcer at seven years after heart-renal transplantation: a case report.

  Hepato-gastroenterology 20040101

• [Particular features of application of proton pump inhibitors (Rabeprazole) in children with the gastroesophageal reflux disease].

  Eksperimental'naia i klinicheskaia gastroenterologiia = Experimental & clinical gastroenterology 20040101

• [Selecting variants of drug treatment of non-complicated duodenal ulcer (based on a study of results of Rabeprazole efficiency)].

  Eksperimental'naia i klinicheskaia gastroenterologiia = Experimental & clinical gastroenterology 20040101

• [Some comparative aspects of treating the gastroesophageal reflux disease eradication].

  Eksperimental'naia i klinicheskaia gastroenterologiia = Experimental & clinical gastroenterology 20040101

• [Clinical and pharmacoeconomic aspects of the antisecretory therapy of gastroesophageal refluxed disease].

  Eksperimental'naia i klinicheskaia gastroenterologiia = Experimental & clinical gastroenterology 20040101

• Effectiveness of proton pump inhibitors: beyond cost.

  Reviews in gastroenterological disorders 20040101

• Retreatment of H. pylori with dual therapy using high doses of rabeprazole or lansoprazole can be effective.

  Alimentary pharmacology & therapeutics 20031201

• Symptom relief in patients with reflux esophagitis: comparative study of omeprazole, lansoprazole, and rabeprazole.

  Journal of gastroenterology and hepatology 20031201

• Gastric acid control with esomeprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole: a five-way crossover study.

  The American journal of gastroenterology 20031201

• Efficacy of triple therapy with rabeprazole for Helicobacter pylori infection in relation to CYP2C19 genotype.

  The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi 20031201

• Comparison of rabeprazole-based four- and seven-day triple therapy and omeprazole-based seven-day triple therapy for Helicobacter pylori infection in patients with peptic ulcer.

  Journal of the Formosan Medical Association = Taiwan yi zhi 20031201

• Direct effects of proton pump inhibitors on histamine release from rat enterochromaffin-like cells.

  European journal of pharmacology 20031128

• Effect of a single oral dose of rabeprazole on nocturnal acid breakthrough and nocturnal alkaline amplitude.

  World journal of gastroenterology 20031115

• Low and high doses of rabeprazole vs. omeprazole for cure of Helicobacter pylori infection.

  Alimentary pharmacology & therapeutics 20031115

• Proton-pump inhibitors in a Navy hospital after a formulary change.

  American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20031115

• Comparison of morning and evening administration of rabeprazole for gastro-oesophageal reflux and nocturnal gastric acid breakthrough in patients with reflux disease: a double-blind, cross-over study.

  Alimentary pharmacology & therapeutics 20031101

• The basis for the decreased response to proton pump inhibitors in gastro-oesophageal reflux disease patients without erosive oesophagitis.

  Alimentary pharmacology & therapeutics 20031101

• [The effect of proton pump inhibitor on intragastric acidity and it relation to S-mephenytoin hydroxylase genetic polymorphism].

  Zhonghua nei ke za zhi 20031101

• Interleukin-1beta genetic polymorphism influences the effect of cytochrome P 2C19 genotype on the cure rate of 1-week triple therapy for Helicobacter pylori infection.

  The American journal of gastroenterology 20031101

• Association between nocturnal bruxism and gastroesophageal reflux.

  Sleep 20031101

• Comparable Helicobacter pylori eradication rates obtained with 4- and 7-day rabeprazole-based triple therapy: a preliminary study.

  Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver 20031101

• Lactoferrin: milking ulcers?

  Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver 20031001

• Use of bovine lactoferrin for Helicobacter pylori eradication.

  Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver 20031001

• [Modern approach to the therapy of gastroesophageal reflux disease].

  Voenno-meditsinskii zhurnal 20031001

• Sequential treatment for Helicobacter pylori eradication in duodenal ulcer patients: improving the cost of pharmacotherapy.

  Alimentary pharmacology & therapeutics 20030915

• Meta-analysis: comparative efficacy of different proton-pump inhibitors in triple therapy for Helicobacter pylori eradication.

  Alimentary pharmacology & therapeutics 20030915

• A new furoxan NO-donor rabeprazole derivative and related compounds.

  Chembiochem : a European journal of chemical biology 20030905

• Comparison of the effect on intragastric pH of a single dose of omeprazole or rabeprazole: which is suitable for on-demand therapy?

  Journal of gastroenterology and hepatology 20030901

• Post-cholecystectomy alkaline reactive gastritis: a randomized trial comparing sucralfate versus rabeprazole or no treatment.

  European journal of gastroenterology & hepatology 20030901

• [A prospective study on rabeprazole-based triple therapy for Helicobacter pylori eradication in patients with peptic ulcer].

  The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi 20030801

• Rabeprazole in a one-week eradication therapy of Helicobacter pylori: comparison of different dosages.

  Journal of gastroenterology and hepatology 20030701

• Rabeprazole treatment attenuated Helicobacter pylori-associated gastric mucosal lesion formation in Mongolian gerbils.

  Journal of gastroenterology and hepatology 20030701

• High-dose rabeprazole-amoxicillin versus rabeprazole-amoxicillin-metronidazole as second-line treatment after failure of the Japanese standard regimen for Helicobacter pylori infection.

  Alimentary pharmacology & therapeutics 20030701

• Proton-pump inhibitor therapy for acetylsalicylic acid associated upper gastrointestinal symptoms: a randomized placebo-controlled trial.

  Alimentary pharmacology & therapeutics 20030701

• Heartburn severity can predict pathologic oesophageal reflux in gastro-oesophageal reflux disease patients treated with a proton-pump inhibitor.

  Alimentary pharmacology & therapeutics 20030701

• Assessment of potential digoxin-rabeprazole interaction after formulary conversion of proton-pump inhibitors.

  American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20030701

• [All proton pump inhibitors are equally efficacious in standard dosages].

  Lakartidningen 20030619

• Acid inhibition on the first day of dosing: comparison of four proton pump inhibitors.

  Alimentary pharmacology & therapeutics 20030615

• Time-dependent amplified pharmacokinetic and pharmacodynamic responses of rabeprazole in cytochrome P450 2C19 poor metabolizers.

  Pharmacotherapy 20030601

• [In-vitro activity of rabeprazole, lansoprazole, and esomeprazole against Helicobacter pylori].

  Zhonghua liu xing bing xue za zhi = Zhonghua liuxingbingxue zazhi 20030601

• Rabeprazole is superior to omeprazole for the inhibition of peptone meal-stimulated gastric acid secretion in Helicobacter pylori-negative subjects.

  Alimentary pharmacology & therapeutics 20030501

• A proton-pump inhibitor, rabeprazole, improves ventilatory function in patients with asthma associated with gastroesophageal reflux.

  Scandinavian journal of gastroenterology 20030501

• Differential drug-induced mRNA expression of human CYP3A4 compared to CYP3A5, CYP3A7 and CYP3A43.

  European journal of pharmacology 20030411

• Meal-stimulated gastric acid secretion and integrated gastric acidity in gastro-oesophageal reflux disease.

  Alimentary pharmacology & therapeutics 20030401

• Determination of the reduction in gastric acidity necessary to prevent pathological oesophageal reflux in patients with gastro-oesophageal reflux disease treated with a proton pump inhibitor.

  Alimentary pharmacology & therapeutics 20030401

• Safety and efficacy of 7-day rabeprazole- and omeprazole-based triple therapy regimens for the eradication of Helicobacter pylori in patients with documented peptic ulcer disease.

  Alimentary pharmacology & therapeutics 20030401

• Reductions in symptom distress reported by patients with moderately severe, nonerosive gastroesophageal reflux disease treated with rabeprazole.

  Digestive diseases and sciences 20030401

• A third-line levofloxacin-based rescue therapy for Helicobacter pylori eradication.

  Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver 20030401

• Systematic review: Rabeprazole-based therapies in Helicobacter pylori eradication.

  Alimentary pharmacology & therapeutics 20030315

• Eradication of Helicobacter pylori increases nocturnal intragastric acidity during dosing with rabeprazole, omeprazole, lansoprazole and placebo.

  Alimentary pharmacology & therapeutics 20030315

• Different contribution of CYP2C19 in the in vitro metabolism of three proton pump inhibitors.

  Biological & pharmaceutical bulletin 20030301

• High eradication rates of Helicobacter pylori with a new sequential treatment.

  Alimentary pharmacology & therapeutics 20030301

• Rabeprazole-based therapy in the management of symptomatic gastroesophageal reflux disease.

  The American journal of gastroenterology 20030301

• Spectrophotometric and chromatographic determination of rabeprazole in presence of its degradation products.

  Journal of pharmaceutical and biomedical analysis 20030226

• Randomized controlled study of rabeprazole, levofloxacin and rifabutin triple therapy vs. quadruple therapy as second-line treatment for Helicobacter pylori infection.

  Alimentary pharmacology & therapeutics 20030215

• A randomized, double-blind trial of the efficacy and safety of 10 or 20 mg rabeprazole compared with 20 mg omeprazole in the maintenance of gastro-oesophageal reflux disease over 5 years.

  Alimentary pharmacology & therapeutics 20030201

• Time-dependent transcriptional induction of CYP1A1, CYP1A2 and CYP1B1 mRNAs by H+/K+ -ATPase inhibitors and other xenobiotics.

  Xenobiotica; the fate of foreign compounds in biological systems 20030201

• Significant enhancement of gastric mucin content after rabeprazole administration: its potential clinical significance in acid-related disorders.

  Digestive diseases and sciences 20030201

• Efficacy of triple therapy comprising rabeprazole, amoxicillin and metronidazole for second-line Helicobacter pylori eradication in Japan, and the influence of metronidazole resistance.

  Alimentary pharmacology & therapeutics 20030101

• Effect of different proton pump inhibitors, differences in CYP2C19 genotype and antibiotic resistance on the eradication rate of Helicobacter pylori infection by a 1-week regimen of proton pump inhibitor, amoxicillin and clarithromycin.

  Alimentary pharmacology & therapeutics 20030101

• Impact of clarithromycin resistance and CYP2C19 genetic polymorphism on treatment efficacy of Helicobacter pylori infection with lansoprazole- or rabeprazole-based triple therapy in Japan.

  European journal of gastroenterology & hepatology 20030101

• Effects of rabeprazole sodium on gastric emptying, electrogastrography, and fullness.

  Digestive diseases and sciences 20030101

• [Medico-economic efficacy of eradication schemes in helicobacter infections in patients with duodenal ulcers].

  Eksperimental'naia i klinicheskaia gastroenterologiia = Experimental & clinical gastroenterology 20030101

• Safety and efficacy of rabeprazole in gastroesophageal reflux disease: report of a multicenter study.

  Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology 20030101

• [Combination therapy of chronic pancreatitis (double-blind, placebo-controlled, pilot studies)].

  Eksperimental'naia i klinicheskaia gastroenterologiia = Experimental & clinical gastroenterology 20030101

• Nocturnal gastric acid breakthrough during the administration of rabeprazole and ranitidine in Helicobacter pylori-negative subjects: effects of different regimens.

  Journal of gastroenterology 20030101

• [Use of proton pump inhibitors in the treatment of gastroesophageal reflux disease].

  Klinicheskaia meditsina 20030101

• An overview of proton pump inhibitors.

  Gastroenterology nursing : the official journal of the Society of Gastroenterology Nurses and Associates 20030101

• [Evaluation of the efficacy of pariet in patients with gastroesophageal reflux disease with thoracic pain not connected with cardiac disease].

  Eksperimental'naia i klinicheskaia gastroenterologiia = Experimental & clinical gastroenterology 20030101

• [Comparative clinical and economic efficiency of new generation proton pump inhibitors in the treatment of gastroesophageal reflux].

  Eksperimental'naia i klinicheskaia gastroenterologiia = Experimental & clinical gastroenterology 20030101

• [Therapy with cytokines and thymic factors in a complicated case of common variable immunodeficiency].

  Revista alergia Mexico (Tecamachalco, Puebla, Mexico : 1993) 20030101

• Esomeprazole 40 mg provides improved intragastric acid control as compared with lansoprazole 30 mg and rabeprazole 20 mg in healthy volunteers.

  Digestion 20030101

• High-dose rabeprazole/amoxicillin therapy as the second-line regimen after failure to eradicate H. pylori by triple therapy with the usual doses of a proton pump inhibitor, clarithromycin and amoxicillin.

  Hepato-gastroenterology 20030101

• [Comparative effectiveness of the antisecretory action of rabeprazole and esomeprazole in people with rapid metabolism of proton pump inhibitors].

  Eksperimental'naia i klinicheskaia gastroenterologiia = Experimental & clinical gastroenterology 20030101

• [Comparative efficacy of proton pump inhibitors in children].

  Eksperimental'naia i klinicheskaia gastroenterologiia = Experimental & clinical gastroenterology 20030101

• Not a usual suspect; rabeprazole therapy presenting as a severe neuropsychiatric illness: case report.

  International journal of psychiatry in medicine 20030101

• The pharmacology and clinical relevance of proton pump inhibitors.

  Current gastroenterology reports 20021201

• Treatment and management of Helicobacter pylori infection.

  Current gastroenterology reports 20021201

• Eradication rates of clarithromycin-resistant Helicobacter pylori using either rabeprazole or lansoprazole plus amoxicillin and clarithromycin.

  Alimentary pharmacology & therapeutics 20021101

• Restoration of acid secretion following treatment with proton pump inhibitors.

  Gastroenterology 20021101

• Drug interaction of tacrolimus and proton pump inhibitors in renal transplant recipients with CYP2C19 gene mutation.

  Transplantation proceedings 20021101

• Rabeprazole improves health-related quality of life in patients with erosive gastroesophageal reflux disease.

  Digestive diseases and sciences 20021101

• Effects of rabeprazole, lansoprazole and omeprazole on intragastric pH in CYP2C19 extensive metabolizers.

  Alimentary pharmacology & therapeutics 20021001

• Sequential eradicating therapy: a treatment that does not discriminate Helicobacter pylori strains in patients with nonulcer dyspepsia?

  The American journal of gastroenterology 20021001

• A new serum antibody test kit (E plate) for evaluation of Helicobacter pylori eradication.

  Internal medicine (Tokyo, Japan) 20021001

• [Antisecretory effect of losec and pariet in peptic ulcer therapy].

  Voenno-meditsinskii zhurnal 20021001

• Rabeprazole: pharmacokinetics and pharmacokinetic drug interactions.

  Die Pharmazie 20020901

• [The short term effect of rabeprazol versus omeprazole on symptom relief of duodenal ulcer].

  Zhonghua nei ke za zhi 20020901

• Proton pump inhibitors: an update.

  American family physician 20020715

• The efficacy of lafutidine in improving preoperative gastric fluid property: a comparison with ranitidine and rabeprazole.

  Anesthesia and analgesia 20020701

• Randomized open trial for comparison of proton pump inhibitors in triple therapy for Helicobacter pylori infection in relation to CYP2C19 genotype.

  Journal of gastroenterology and hepatology 20020701

• Measuring symptom distress and health-related quality of life in clinical trials of gastroesophageal reflux disease treatment: further validation of the Gastroesophageal Reflux Disease Symptom Assessment Scale (GSAS).

  Digestive diseases and sciences 20020701

• Effects of rabeprazole, 20 mg, or esomeprazole, 20 mg, on 24-h intragastric pH and serum gastrin in healthy subjects.

  Alimentary pharmacology & therapeutics 20020701

• Impact of proton pump inhibitor utilization patterns on gastroesophageal reflux disease-related costs.

  Managed care (Langhorne, Pa.) 20020701

• Single vs. double dose of a proton pump inhibitor in triple therapy for Helicobacter pylori eradication: a meta-analysis.

  Alimentary pharmacology & therapeutics 20020601

• Rabeprazole in nonerosive gastroesophageal reflux disease: a randomized placebo-controlled trial.

  The American journal of gastroenterology 20020601

• A modification of the quininium resin test for assessing gastric acidity.

  Alimentary pharmacology & therapeutics 20020501

• Primary hyperparathyroidism with duodenal ulcer and H. pylori infection.

  Internal medicine (Tokyo, Japan) 20020501

• [Regeneration of the gastric epitheliocytes during treatment of duodenal ulcer with pariet].

  Voenno-meditsinskii zhurnal 20020401

• Review article: rabeprazole-based therapy in Helicobacter pylori eradication.

  Alimentary pharmacology & therapeutics 20020301

• Onset of symptom relief with rabeprazole: a community-based, open-label assessment of patients with erosive oesophagitis.

  Alimentary pharmacology & therapeutics 20020301

• Integrated acidity and rabeprazole pharmacology.

  Alimentary pharmacology & therapeutics 20020301

• A randomized, double-blind, comparative study of standard-dose rabeprazole and high-dose omeprazole in gastro-oesophageal reflux disease.

  Alimentary pharmacology & therapeutics 20020301

• Acute fulminant hepatitis after treatment with rabeprazole and terbinafine: is rabeprazole the culprit?

  Archives of internal medicine 20020211

• [Dual therapy for Helicobacter pylori resistance to anti microbial agents].

  Nihon rinsho. Japanese journal of clinical medicine 20020201

• [Proton pump inhibitor-based quadruple therapy regimen for Helicobacter pylori infection].

  Nihon rinsho. Japanese journal of clinical medicine 20020201

• [High dose dual PPI/AMPC therapy for the treatment of Helicobacter pylori infection after failure of usual standard triple PPI/AMPC/CAM therapy: CYP2C19 polymorphism].

  Nihon rinsho. Japanese journal of clinical medicine 20020201

• [Second line treatment regimen of PPI + AMPC + MNZ for patients with clarithromycin-resistant Helicobacter pylori infection].

  Nihon rinsho. Japanese journal of clinical medicine 20020201

• [Minocycline-containing eradication therapy for patients with clarithromycin-resistant Helicobacter pylori infection].

  Nihon rinsho. Japanese journal of clinical medicine 20020201

• [Continuation of acid suppression therapy after H. pylori eradication].

  Nihon rinsho. Japanese journal of clinical medicine 20020201

• [Proton pump inhibitors: Rabeprazole].

  Nihon rinsho. Japanese journal of clinical medicine 20020201

• [Cause and prevention of nocturnal gastric acid breakthrough].

  Nihon rinsho. Japanese journal of clinical medicine 20020201

• Effects of lansoprazole and rabeprazole on tacrolimus blood concentration: case of a renal transplant recipient with CYP2C19 gene mutation.

  Transplantation 20020127

• Drug combinations with amoxycillin reduce selection of clarithromycin resistance during Helicobacter pylori eradication therapy.

  International journal of antimicrobial agents 20020101

• Treatment with a proton pump inhibitor promotes corpus gastritis in patients with Helicobacter pylori-infected antrum-predominant gastritis.

  Alimentary pharmacology & therapeutics 20020101

• [Pharma-clinics medication of the month. Rabeprazole (Pariet)].

  Revue medicale de Liege 20020101

• The effects of rabeprazole on parietal cells and enterochromaffin-like cells in rats: a comparison with omeprazole.

  Journal of gastroenterology 20020101

• Rabeprazole: quest for the best PPI.

  Journal of gastroenterology 20020101

• [Inhibitors of proton pump in the treatment of non-ulcer functional dyspepsia of the reflux-like type].

  Eksperimental'naia i klinicheskaia gastroenterologiia = Experimental & clinical gastroenterology 20020101

• [Regeneration of the esophagus epitheliocytes. Evaluation of pariet efficacy in the treatment of patients with reflux esophagitis].

  Eksperimental'naia i klinicheskaia gastroenterologiia = Experimental & clinical gastroenterology 20020101

• Rabeprazole.

  Journal of postgraduate medicine 20020101

• Are proton pump inhibitors the first choice for acute treatment of gastric ulcers? A meta analysis of randomized clinical trials.

  BMC gastroenterology 20020101

• [Evaluation of efficacy, safety and tolerability rabeprazole in treatment of acid-peptic diseases ].

  Arquivos de gastroenterologia 20020101

• Polymorphism of CYP2C19 and gastric emptying in patients with proton pump inhibitor-resistant gastric ulcers.

  The Journal of international medical research 20020101

• Patients have treatment preferences: a multicentre, double-blind, crossover study comparing rabeprazole and omeprazole.

  Current medical research and opinion 20020101

• [Effectiveness of pariet (rabeprazole) in the treatment of gastroesophageal reflux disease (at the reflux-esophagitis stage)].

  Eksperimental'naia i klinicheskaia gastroenterologiia = Experimental & clinical gastroenterology 20020101

• [Seven-day antihelicobacter therapy of duodenal ulcer associated with Helicobacter pylori and prospects for treating patients].

  Eksperimental'naia i klinicheskaia gastroenterologiia = Experimental & clinical gastroenterology 20020101

• [Pariet in eradication therapy plans].

  Eksperimental'naia i klinicheskaia gastroenterologiia = Experimental & clinical gastroenterology 20020101

• Eradication therapy with rabeprazole versus omeprazole in the treatment of active duodenal ulcer.

  Digestion 20020101

• [Esophageal epithelial cells renewal in evaluation of the pariet efficacy in the treatment of patients with reflux esophagitis].

  Eksperimental'naia i klinicheskaia gastroenterologiia = Experimental & clinical gastroenterology 20020101

• [A case of the successful treatment of the esophageal leukoplakia with rabeprazole].

  Eksperimental'naia i klinicheskaia gastroenterologiia = Experimental & clinical gastroenterology 20020101

• [Clinical aspects of using pariet in treating chronic pancreatitis].

  Eksperimental'naia i klinicheskaia gastroenterologiia = Experimental & clinical gastroenterology 20020101

• [Rhabdomyolysis during treatment with rabeprazole (Pariel), a proton pump inhibitor combined with domperidone (Peridys)].

  Therapie 20020101

• Duodenal mucosa-associated lymphoid tissue lymphoma treated by eradication of Helicobacter pylori: report of 2 cases including EUS findings.

  Gastrointestinal endoscopy 20011201

• Effects of CYP2C19 genotypic differences in the metabolism of omeprazole and rabeprazole on intragastric pH.

  Alimentary pharmacology & therapeutics 20011201

• Rabeprazole-based 3-day and 7-day triple therapy vs. omeprazole-based 7-day triple therapy for the treatment of Helicobacter pylori infection.

  Alimentary pharmacology & therapeutics 20011201

• Helicobacter pylori eradication: do we have another ace up our sleeve?

  Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver 20011201

• Effects of CYP2C19 gene polymorphism on cure rates for Helicobacter pylori infection by triple therapy with proton pump inhibitor (omeprazole or rabeprazole), amoxycillin and clarithromycin in Japan.

  Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver 20011101

• Optimizing acid-suppression therapy.

  Managed care (Langhorne, Pa.) 20011001

• [Modern means of anti-Helicobacter therapy].

  Voenno-meditsinskii zhurnal 20011001

• [Comparative study of proton pump inhibitors].

  Orvosi hetilap 20010909

• Decreasing oesophageal acid exposure in patients with GERD: a comparison of rabeprazole and omeprazole.

  Alimentary pharmacology & therapeutics 20010901

• Efficacy of triple therapy with rabeprazole for Helicobacter pylori infection and CYP2C19 genetic polymorphism.

  Alimentary pharmacology & therapeutics 20010901

• [Comparative antisecretory activity of famotidine, omeprazole, and rabeprazole (pariet) in ulcer disease based on daily pH-monitoring].

  Voenno-meditsinskii zhurnal 20010901

• Comparison of the kinetic disposition of and serum gastrin change by lansoprazole versus rabeprazole during an 8-day dosing scheme in relation to CYP2C19 polymorphism.

  European journal of clinical pharmacology 20010901

• Cost-effectiveness of proton-pump inhibitors for maintenance therapy of erosive reflux esophagitis.

  American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20010715

• Acute fulminant hepatitis after treatment with rabeprazole and terbinafine.

  Archives of internal medicine 20010709

• A randomized open trial for comparison of proton pump inhibitors, omeprazole versus rabeprazole, in dual therapy for Helicobacter pylori infection in relation to CYP2C19 genetic polymorphism.

  Journal of gastroenterology and hepatology 20010701

• Healing and relapse rates in gastroesophageal reflux disease treated with the newer proton-pump inhibitors lansoprazole, rabeprazole, and pantoprazole compared with omeprazole, ranitidine, and placebo: evidence from randomized clinical trials.

  Clinical therapeutics 20010701

• Pharmacodynamic effects and kinetic disposition of rabeprazole in relation to CYP2C19 genotypes.

  Alimentary pharmacology & therapeutics 20010601

• Laryngopharyngeal reflux symptoms improve before changes in physical findings.

  The Laryngoscope 20010601

• Inhibitory action of a novel proton pump inhibitor, rabeprazole, and its thioether derivative against the growth and motility of clarithromycin-resistant Helicobacter pylori.

  Helicobacter 20010601

• Strategy for retreatment of therapeutic failure of eradication of Helicobacter pylori infection.

  Journal of gastroenterology and hepatology 20010601

• Effects of genotypic differences in CYP2C19 status on cure rates for Helicobacter pylori infection by dual therapy with rabeprazole plus amoxicillin.

  Pharmacogenetics 20010601

• CYP2C19 genotype and pharmacokinetics of three proton pump inhibitors in healthy subjects.

  Pharmaceutical research 20010601

• Proton pump inhibitors and their drug interactions: an evidence-based approach.

  European journal of gastroenterology & hepatology 20010501

• New-generation proton pump inhibitors: overcoming the limitations of early-generation agents.

  European journal of gastroenterology & hepatology 20010501

• [Safety profile of pariet clinical use (a literature review)].

  Voenno-meditsinskii zhurnal 20010501

• [H2 receptor antagonists and proton pump inhibitors: principles and rules of use].

  La Revue du praticien 20010415

• Effects of pirenzepine, omeprazole, lansoprazole, and rabeprazole on human neutrophil functions.

  Canadian journal of anaesthesia = Journal canadien d'anesthesie 20010401

• 4-day triple therapy with rabeprazole, amoxicillin and clarithromycin in the eradication of Helicobacter pylori in patients with peptic ulcer disease--A pilot study.

  Zeitschrift fur Gastroenterologie 20010401

• [Pariet in current patterns of eradication of Helicobacter pylori infection].

  Voenno-meditsinskii zhurnal 20010401

• Five-day proton pump inhibitor-based quadruple therapy regimen is more effective than 7-day triple therapy regimen for Helicobacter pylori infection.

  Alimentary pharmacology & therapeutics 20010301

• Efficacy of rabeprazole once daily for acid-related disorders.

  Digestive diseases and sciences 20010301

• The effect of oral administration of Lactobacillus GG on antibiotic-associated gastrointestinal side-effects during Helicobacter pylori eradication therapy.

  Alimentary pharmacology & therapeutics 20010201

• [Selection of antibiotics and planning of eradication for H. pylori infection].

  Nihon rinsho. Japanese journal of clinical medicine 20010201

• [A new blocker of proton pump pariet: pharmacological properties and effectiveness of clinical application].

  Klinicheskaia meditsina 20010101

• Relative efficacies of gastric proton-pump inhibitors on a milligram basis: desired and undesired SH reactions. Impact of chirality.

  Scandinavian journal of gastroenterology. Supplement 20010101

• Rabeprazole: an update of its use in acid-related disorders.

  Drugs 20010101

• Effects of benzimidazole derivatives on cytochrome P450 1A1 expression in a human hepatoma cell line.

  Xenobiotica; the fate of foreign compounds in biological systems 19970101